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ABSTRACT 
The molecular actions initiated by the steroid hormone estrogen elicit a multitude of 
biological effects in physiological and pathophysiological processes. Estrogen acts via its 
cognate steroid hormone receptor, estrogen receptor alpha (ERα) or beta (ERβ), to fulfill these 
biological processes. The studies reported here investigate estrogen’s action via ERα in uterine 
physiology and ovarian pathophysiology and is written in two parts. The first part is an 
investigation of ERα and its downstream target Hif2α in the uterus during embryo implantation. 
The later part of the dissertation discusses the role that ERα plays in ovarian tumorigenesis.   
Both humans and rodents exhibit hemochorial placentation, an invasive form of embryo 
implantation which is characterized by intimate contact of the implanted embryo with maternal 
blood. Implantation is initiated when the embryo first attaches to the uterine epithelial cells and 
invades through these cells to the underlying stroma. This process triggers the uterine stromal 
cells to undergo proliferation and differentiation to form the decidua, a secretary maternal tissue 
that provides the necessary nutrients to support embryonic life prior to placentation. Through the 
development of knockout mouse models, it is known that ERα, the predominant estrogen 
receptor in the uterus, is essential for the embryo to attach to these cells prior to invasion. 
However, we have uncovered for the first time the essential role of ERα in uterine stromal cell 
differentiation during embryo implantation. We have developed a conditional knockout mouse 
model, termed ERαd/d, which has ERα deleted in all cell types which express progesterone 
receptor (PR).  By employing artificially induced decidualization we know that ERα in the 
uterine stromal cells is essential for proliferation and decidualization.  
To date very few molecules have been shown to be regulated by estrogen in the uterine 
stromal cells that are essential for decidualization. Our laboratory has shown that it is local 
estrogen production acting via ERα within the uterine stromal cells that drives and sustains the 
decidualization response. Furthermore this local estrogen production regulates endothelial PAS 
domain protein 1 (EPAS1), also called hypoxia-inducible factor 2 alpha (Hif2α).  Hif2α is a 
transcription factor that has been shown to be regulated by hypoxic conditions and regulates 
molecules essential for an angiogenesis response. In order to study the functional role of 
Hif2α, we have created a conditional knockout of the Hif2α gene which has Hif2α knocked out 
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in all cells expressing PR. This conditional knockout mouse, termed Hif2αd/d, is infertile. During 
pregnancy embryos travel to the uterine lumen and attach to uterine epithelial cells. This 
attachment elicits an initial decidual response. This is the first in vivo model to show that embryo 
attachment and not embryo invasion through the epithelial cells provokes a stromal cell decidual 
response. In absence of Hif2α, stromal cells begin the process of decidualization and display 
alkaline phosphatase activity, a marker of differentiation. However, prolactin related protein 
(PRP), a decidual marker induced later in the decidualization process, is absent in the Hif2αd/d 
uterus indicating that the terminal differentiation of stromal cells is compromised in absence of 
Hif2α. Furthermore, without Hif2α in the stromal cells, angiogenesis at the early stages of 
pregnancy is impaired as marked by a downregulation of an endothelial cell marker, PECAM. 
Understanding downstream molecules of Hif2α will undoubtedly give insight into the molecular 
pathways essential for implantation. The role that uterine ERα and its downstream target, 
Hif2α,  plays in the early phases of pregnancy will be the topic of chapter 2.   
The second part of this dissertation focuses on the role that ERα plays in the 
pathophysiology associated with ovarian tumorigenesis. We have generated an animal model 
which forms epithelial ovarian tumors with 100% penetrance. This animal model is a conditional 
knockout for the ERα, termed ERαd/d. This animal shows a lack of ERα expression in the 
pituitary which leads to a lack of negative estrogen feedback on the hypothalamus-pituitary-
ovarian axis resulting in high serum levels of luteinizing hormone, estradiol, progesterone and 
testosterone. Interestingly, ovarian expression of ERα in this animal model remains intact. We 
have shown that by treating animals with letrozole, an aromatase inhibitor, that ovarian tumor 
volume is decreased compared to untreated animals, indicating a novel role of ERα in ovarian 
tumorigenesis. This animal model mimics the genetic profile of human serous epithelial ovarian 
carcinoma and provides a novel tool to study epithelial ovarian tumorigenesis for two reasons: 1) 
tumors form slowly over the course of the animal’s life mimicking human epithelial ovarian 
tumors and 2) ovarian tumors form due to a physiological perturbation and not a mechanical 
perturbation, such as intra-bursal injection to induce oncogene expression, further mimicking the 
human ovarian tumor formation. This animal model will aid in our understanding of how 
epithelial ovarian tumors form and will likely lead to the discovery of treatments and/or 
diagnostic tools for this disease.  
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CHAPTER 1: Literature Review - Part I 
The American College of Obstetricians and Gynecologists (ACOG) estimates that 15% 
of all known human pregnancies will end in miscarriage. The actual number of failed 
pregnancies is probably significantly higher since many miscarriages or early pregnancy loss is 
not detected by the mother. Due to extensive research in the area of pregnancy, the human 
population is now aware of factors which increase the risks of pregnancy loss such as alcohol 
consumption or cigarette smoking by the mother. However, molecular players associated with 
pregnancy loss remain unclear. 
 To  better understand why miscarriages occur, the process of implantation and stages 
leading to the establishment of pregnancy need to be further investigated.  Assisted reproductive 
technologies (ART) have become the method of choice for those who have recurring 
miscarriages. Undoubtedly with a better understanding of the implantation process, the success 
of ART could be enhanced significantly. 
 Ethically, the scientific analysis of human pregnancy remains a difficult subject of 
research. We therefore, rely on animal models that mimic the pregnancy process of the human to 
better understand the complexity of this phenomenon.  
 Although the process of implantation and placentation varies greatly among mammalian 
species, the human and rodent exhibit hemochorial placentation. In these species, implantation is 
invasive in nature allowing for the maternal and fetal tissues to come into intimate contact with 
each other (1-2). We therefore use the mouse as an animal model to study the processes of 
implantation and pregnancy. Furthermore, due to the power of genetics, this animal model also 
allows us to explore the function of target molecules in vivo by using knockout strategies. Part I 
of this dissertation discusses molecular pathways underlying the physiology of pregnancy in the 
mouse.   
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1.1 Implantation 
Implantation of the embryo into the uterine wall occurs in three distinct steps: apposition, 
adhesion, and invasion.  In the mouse after the oocyte is released from the ovary, fertilization 
begins in the oviduct when the sperm meets the egg. The fertilized egg will then take 4 days for 
the journey through the oviduct into the uterus where the implantation process will begin. 
 The embryo will first become closely apposed to the luminal epithelium of the uterus 
beginning on day 4 of pregnancy. We denote day 1 of pregnancy as the day in which we see the 
copulatory plug. The next phase is termed adhesion. At this point, the trophectoderm becomes 
tightly adhered to the luminal epithelium. The invasive phase of implantation occurs in the third 
stage of the process. At this time, the trophectoderm will penetrate the luminal epithilium and 
progress into the uterine stromal tissue (3-5). Subsequently, the implanting embryo will initiate 
stromal cell proliferation and differentiation into secretory decidual cells, a process termed as 
decidualization.  
 It is known that implantation and decidualization are under direct control of steroid 
hormones estrogen (E) and progesterone (P). In the mouse, there is a “nidatory surge” of ovarian 
E on day 4 of pregnancy (6-7). This surge of E has been shown to be critical for the initiation of 
implantation. Experimentally, this phenomenon has been clearly established in the delayed 
implantation mouse model. In this model, if pregnant animals are ovariectomized on day 4 
morning, thereby removing the circulating steroid hormones, the embryo will not implant. 
Progesterone is essential to prepare the uterus to receive the implanting embryo. If P is given the 
embryo will be maintained in the free-floating state within the uterine lumen. However, if several 
days of P administration are followed by only a single dose of E, the embryo will immediately 
begin the implantation process (8-9). This experimental model is a convenient system to study 
the downstream targets of E action in the early stages of implantation.   
 Implantation occurs in the presence of the correct hormonal milleu, termed as the 
“window of implantation”. Under the influence of E and P, the uterus will be in one of three 
phases of receptivity: neutral, receptive, and refractory. During delayed implantation, 
administration of P will leave the uterus in a neutral state. In the presence of E, the uterus will 
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become receptive and the implantation process will begin. However 24-36 hours after the 
administration of E, the uterus will become refractory and implantation will no longer occur (10-
11).  
 
1.2 Decidualization 
Following  embryo apposition, adhesion, and invasion through the luminal epithilium, the 
process of decidualization is initiated. The invasion of the embryo into the uterus leads to several 
rounds of stromal cell proliferation followed by differentiation (12). The resulting tissue, termed 
the decidua, exhibits morphologically and biochemically different traits than the originating 
stromal cell. The decidua is thought to secrete hormones and cytokines necessary for 
implantation as well as provide an immune barrier to the mother from the allogenic embryo (13-
15).  
 The embryo implants into the anti-mesometrial area of the uterus and invades toward the 
mesometrial area. During implantation, the anti-mesometrial area will form a primary decidual 
zone surrounding the embryo on day 5 of pregnancy and is initially devoid of blood vessels. The 
decidualization will span into a secondary decidualization zone beginning on day 6 of pregnancy 
forming the decidua capsularis (7). In the mesometrial region, the differentiated stroma will 
become the decidua basalis. The decidua eventually will be replaced by the placenta.  
 The proliferation and differentiation of stromal cells during decidualization is also 
regulated by steroid hormones E and P (16). We can analyze the decidualization process in vivo 
in absence of the embryo using the artificial decidualization model system (ADR). In this 
experimental model, non-pregnant animals are ovariectomized followed by a priming of E. 
Estrogen levels are critical to prepare the uterus for decidualization (17).  Animals will then be 
administered either P or E plus P followed by a stimulus, such as oil injection into the uterine 
lumen, to induce decidualization (18). In this experimental model blockage of progesterone 
receptor (PR) and estrogen receptor (ER) activities by anti-progestins or anti-estrogens will 
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impair decidualization indicating crucial roles of PR and ER in the regulation of this process 
(19).  
 
1.3 Angiogenesis of Decidua 
Development of the mammalian embryo depends on the successful initiation of 
implantation, formation of decidua followed by placentation. The formation of the hemochorial 
placenta, common to both the rodent and human, consists of three layers. The outer layer is of 
maternal origin and is composed of decidual cells of the uterus. This layer contains maternal 
vasculature that brings blood to/from the implantation site. The middle region is termed the 
"junctional" area. This area is where the fetal placenta attaches to the uterus. The inner layer is 
composed of highly branched villi that are designed for efficient nutrient exchange. This area is 
also known as the labyrinth layer and is derived from a trophoblast lineage (2). The villi will be 
bathed in maternal blood in order to facilitate transfer of nutrients. 
 The formation of a mature placenta is not evident until E12.5. The first step in labyrinth 
formation is the chorioallantoic attachment and this occurs at E8.5 (2). At this point fetal blood 
vessels will begin to grow. Prior to the chorioallantoic attachment, the maternal decidua must be 
fully vascularized in order to support the growing embryo.  
 In the mouse, a conclusive sign of implantation initiation is an increased uterine vascular 
permeability at the sites of blastocyst apposition. This heightened localized vascular permeability 
can be visualized by discrete blue bands using an intravenously injected blue dye at the time of 
embryo attachment and is considered one of the earliest prerequisite events for the process of 
implantation. Vascular endothelial growth factor (VEGF), a potent endothelial cell mitogen that 
mediates rapid endothelial proliferation, is expressed in the decidua on day 5 morning during the 
initiation of vascular permeability (26).  It is widely believed that VEGF plays a key role in 
angiogenesis within the uterine decidua during pregnancy (27-29). 
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 During decidualization, endothelial cells are recruited to the deciduas, initiating 
angiogenesis (20). The establishment of a vascular network in the decidua is essential for 
embryonic growth. It is known that steroid hormones E and P play critical roles in the process of 
angiogenesis; however, their specific roles in this process remain controversial. Reports have 
shown that E increases vascular permeability, but does not increase endothelial cell proliferation 
(21). In contrast, others observed a rapid induction of endometrial endothelial cell proliferation 
within 24 h of E treatment in ovariectomized mice, suggesting a rapid angiogenic response (22). 
Contradicting this observation, Ma et al. concluded that E promotes uterine vascular permeability 
but profoundly inhibits angiogenesis, whereas P stimulates angiogenesis with little effect on 
vascular permeability (23). The difference in experimental models used in these studies may be a 
cause of inconsistency concerning the issue of steroid hormone regulation of angiogenesis prior 
to placentation. 
 We are interested in understanding the role that E plays in the regulation of angiogenesis 
prior to placentation. Using an in vivo model of artificially delayed implantation, we have clearly 
established that local production of E in the uterine stromal cells promotes decidualization and 
angiogenesis prior to placentation (24). By treating mice with aromatase inhibitor, Das et al. 
show that inhibiting local production of E reduces angiogenesis in the decidua and impairs 
expression of angiopoietins. Furthermore we have shown that Connexin 43, a gap junction 
protein, is regulated by estrogen during implantation and is critical for angiogenesis in the 
decidua (25). These studies have clearly established a role of E in angiogenesis of the decidua 
prior to placentation. 
  
1.4 Estrogen Receptor Alpha (ERα) Function in the Uterus during Early Pregnancy 
The molecular actions of the steroid hormone E are mediated by the cognate steroid 
hormone receptors, estrogen receptors alpha and beta. Estrogen receptors act as transcription 
factors to regulate down-stream target genes. Global ERα knockout mice are infertile and have 
hypoplastic uteri (30). Exposure to estrogen fails to induce uterine hypertrophy in ERα knockout 
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mice. Furthermore embryo transfer experiments indicate that uterine ERα is essential for embryo 
implantation (31).  In contrast ERβ knockout mice are subfertile, but can carry pregnancies to 
term and their uteri respond to estrogen treatment (32).  The cause of infertility in these mice is a 
result of ovarian dysfunction. Evidence from these knockout models clearly indicates that ERα is 
the predominant regulator of estrogen function in the uterus.  
Prior publications have concluded that ERα is essential for embryo implantation, but is 
indispensible for uterine decidualization (31). These studies were carried out using an ERα 
global knockout mouse which forms alternative splice variants of the ERα gene (30, 33). 
Alternative splice variants of ERα in the knockout mouse could be functional. Therefore, the 
role of ERα in uterine stromal cell differentiation needs to be reexamined using alternative 
models.  
The transcription factor ERα classically acts by binding to estrogen response elements 
(EREs) in the promoter region of target genes. Alternatively, ERα has the ability to bind to other 
transcription factors to regulate target genes, a molecular event termed the non-classical tethering 
mechanism of ERα. Generation of a non-classical receptor knock-in mouse allows an 
investigator to pinpoint the transcription mechanism of ERα signaling during physiological 
processes in vivo (34). This knock-in animal model lacks the ability of ERα to bind directly to 
EREs. In order to determine downstream targets of ERα in uterine function, it is imperative to 
determine by which of these genomic transcription mechanisms ERα acts.  
 
1.5 Hypoxia-inducible Factor 2 alpha (Hif2α)  
Hypoxia-inducible factor 2 alpha (Hif2α), also termed endothelial PAS domain protein 1 
(EPAS1), is a transcription factor that binds to hypoxia response elements in genomic DNA and 
is known to regulate genes involved in erythropoiesis, angiogenesis, metastasis, and proliferation 
(35). Hif2α is thought to be constitutively expressed and regulated by post-transcriptional 
mechanisms involving hypoxia (36). Under normoxic conditions, Hif2α is targeted for 
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proteosomal degradation, but stabilized under hypoxic conditions. This stabilized alpha subunit 
then binds to its beta counterpart, ARNT, and becomes transcriptionally active.  
Hif2α has been shown to be present in the mouse uterine stromal cells. Even though 
classical regulation of protein accumulation is thought to be mediated by oxygen levels, previous 
reports have shown that estrogen regulates mRNA levels in uterine stromal cells (37). Peak 
induction of Hif2α occurs 6 hours post estrogen treatment in animals that have been 
ovariectomized. Furthermore, our laboratory has shown that local estrogen production by uterine 
stromal cells induces Hif2α mRNA expression. These findings lead us to believe that 
Hif2α could provide a novel insight into estrogen’s regulation of angiogenesis within the decidua 
prior to placentation.  
 
1.6 Specific Aims 
Aim 1. To investigate the role of ERα and its downstream targets in endometrial stromal cell 
decidualization and angiogenesis: 
a. Elucidate the functional role of ERα in endometrial decidualization and angiogenesis 
during early pregnancy by generating a conditional knockout of ERα.  
b. Analyze the reproductive phenotypes of the ERα knockout females. 
Aim 2. Investigate the function of Hif2α in murine uterine function: 
a. Elucidate the functional role of Hif2α, a target of E, in endometrial angiogenesis 
during early pregnancy by generating a conditional knockout of Hif2α.  
b. Analyze the reproductive phenotypes of the Hif2α knockout females. 
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CHAPTER 2: The Role of Estrogen Receptor Alpha and its Down-stream Target Hypoxia-
inducible Factor 2 Alpha in Uterine Function during Early Pregnancy 
2.1- Abstract 
During early pregnancy, the concerted actions of the steroid hormones estrogen (E) and 
progesterone (P) via their cognate receptors orchestrate the changes in the uterine epithelium that 
make it competent to attach to the blastocyst and initiate the process of implantation. It is 
followed by the proliferation and differentiation of the underlying stromal cells into 
morphologically and functionally distinct decidual cells, which control trophoblast invasion and 
embryonic growth. Concomitant with this cellular transformation, known as decidualization, an 
extensive vascular network develops in the stromal compartment that supports the development 
of the implanted embryo. Although P acting via the progesterone receptor (PR) is essential for 
decidualization, the role of E in this process is less clear. To address this issue, we used the Cre-
Lox strategy to create conditional mutant mice in which estrogen receptor alpha (ERα) 
expression is abolished in the uterus. Strikingly, the uteri of these mutant mice failed to show any 
response to a decidual stimulus, revealing for the first time a critical role of ERα in stromal 
decidualization. Subsequent investigations indicate ERα in the stroma is critical for cell 
proliferation, differentiation and angiogenesis during decidualization.  It is known that local 
estrogen produced by uterine stromal cells drives stromal cell differentiation and vascular 
network formation. Treating mice with aromatase inhibitor indicate that this local E production 
regulates the expression of hypoxia-inducible factor 2 alpha (Hif2α), a transcription factor 
known to promote angiogenesis in other tissues. Hif2α is widely expressed in uterine stromal 
cells during decidualization and is induced by E in the ovariectomized mouse model. To address 
the functional role of this protein, we used the Cre-Lox strategy to create conditional mutant 
mice in which Hif2α expression is abolished in the uterus. These transgenic mice maintain the 
ability to ovulate but are completely infertile revealing for the first time a critical role of Hif2α in 
the uterus in maintaining pregnancy. Further histological examination indicates that embryos 
attach to the uterine luminal epithelial cells of Hif2α conditional knockout mice but fail to 
penetrate through the epithelium on days 5 and 6 of pregnancy. Despite the lack of embryo 
invasion, uterine stromal cells in Hif2α null mice differentiate as marked by alkaline 
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phosphatase activity, an early marker of decidualization. This remarkable phenotype shows for 
the first time that embryo attachment, and not embryo invasion, initiates stromal cell 
decidualiation. Subsequent analysis shows that the decidua of Hif2α conditional knockout mice 
fail to express prolactin-related protein, a terminal marker of decidualization, indicating that 
stromal cells are not able to fully differentiate. Furthermore, the Hif2α conditional knockout 
uterus fails to form a vascular network within the decidua on day 7 of pregnancy. Collectively, 
these results indicate a novel role for uterine ERα and its downstream target Hif2α in the 
regulation of mouse embryo invasion into the stromal compartment, decidualization as well as 
angiogenesis within the decidua prior to placentation.  
 
2.2- Introduction 
 Embryo implantation is regulated by the concerted actions of steroid hormones E and P. 
These hormones act via their individual cognate steroid hormone receptors. Estrogen receptor 
alpha (ERα) is the predominant estrogen receptor in the uterus. Studies involving ERα global 
knockout mice have shown that uterine ERα mediates embryo attachment to the uterine luminal 
epithelium. Subsequent studies using ERα global knockout mice have concluded that ERα is 
dispensable for uterine stromal cell decidualization following embryo implantation (31). Kos et 
al. have determined that the ERα global knockout mice used in these studies express alternative 
splice variants of the ERα gene raising the possibility that a functional form of ERα remains in 
these knockout mice (33). Therefore, the role of ERα in uterine stromal cell decidualization 
warrants further investigation.  
 Recently we reported that local estrogen production by uterine stromal cells is essential 
for stromal cell differentiation and angiogensis within the decidua prior to placentation (24). We 
hypothesize that the molecular actions of local estrogen production are mediated by uterine 
stromal cell ERα. To address the functional role of ERα, we generated a conditional knockout 
mouse.  ERα mice with loxp sites flanking the exon 3 of the ERα gene, ERα floxed mice, were 
generated by Dupont et al. (39). These flox mice were crossed with mice expressing cre-
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recombinase driven by the endogenous progesterone receptor (PR) (38). The conditional 
knockout mice generated are termed, ERαd/d mice. Using this recently developed mouse model 
we show that ERα plays an essential role in uterine stromal cell proliferation, decidualization as 
well as angiogenesis. Identifying down-stream targets of ERα in uterine stromal cells is essential 
to understand embryo implantation and uterine angiogenesis.  
 Previous reports have shown that E regulates the expression of hypoxia-inducible factor 2 
alpha (Hif2α) in uterine stromal cells (24, 37). Hif2α is a transcription factor known to induce 
expression of genes essential for angiogenesis. Because Hif2α is regulated by estrogen during 
pregnancy this protein could be the molecular link pinpointing estrogen action in promoting 
uterine angiogenesis. Our initial immunohistochemical studies indicate that Hif2α is expressed 
in the nucleus of uterine decidual cells during pregnancy. To study the functional role of 
Hif2α, we created conditional knockout mice by crossing mice harboring loxp sites surrounding 
exon 2 of the Hif2α gene with mice expressing cre-recombinase knocked in under the 
endogenous PR. The Hif2α conditional knockout mouse is able to ovulate but is infertile. The 
studies described in this chapter identify Hif2α, a down-stream target of ERα, as an essential 
protein for embryo invasion through the luminal epithelium, stromal cell decidualization as well 
as uterine angiogenesis. 
 
2.3- Results 
ERα is Localized to Uterine Stromal Cells During the Decidualization Phase of Pregnancy 
ERα protein is present in multiple uterine cellular compartments during early pregnancy. 
On day 1 of pregnancy, ERα is localized to the luminal and glandular epithelial cells as well as 
in the stroma (Fig. 2.1 A). Similarly, ERα is present in these same cellular compartments on day 
4 of pregnancy, a time when the embryo will attach to the luminal epithelium (Fig. 2.1 B). On 
day 5 of pregnancy, at the onset of decidualization, ERα is abundantly present in the uterine 
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stromal cells (Fig. 2.1 C). This spatio-temporal localization of ERα indicates that this protein 
may play a role in decidualization.  
 
ERα is Essential for Decidualization during Early Pregnancy 
To understand the functional role of ERα during decidualization, we created a 
conditional knockout mouse for the ERα gene. Mice harboring loxp sites flanking the exon 3 of 
the ERα gene, ERα floxed mice, were crossed with mice expressing cre-recombinase under the 
endogenous PR promoter. The conditional knockout mice are termed ERαd/d mice and the flox 
only control mice are ERαf/f mice.  
ERαd/d mice exhibit an efficient deletion of ERα in the luminal epithelium, glandular 
epithelium and stromal compartment of the uterus (Fig. 2.2 B). As expected, these mice are 
infertile (Table 2.1). 
Both ERαd/d and ERαf/f mice were subjected to artificial decidualization protocol and 
uterine horns are collected 72hrs after administration of a decidual stimulus. ERαf/f mice show a 
robust decidual response after injection of an oil stimulus into the uterine lumen (Fig. 2.2 C). The 
left uterine horn was used as an internal unstimulated control. ERαd/d mice fail to form any 
deciduoma in response to an oil stimulus.  
 
Impaired Decidualization and Angiogenesis in ERαd/d Uteri  
ERαd/d mice fail to form a deciduoma after artificial decidual stimulus. We next 
examined two hallmarks of decidualization and angiogenesis. Alkaline phosphatase activity is an 
indicator of cellular differentiation and platelet/endothelial cell adhesion molecule 1 (PECAM1) 
marks endothelial cells indicating the vascular network formation in the decidua. ERαf/f uterine 
stromal cells show a robust response to the decidual stimulus. The stromal compartment shows a 
high level of alkaline phosphatase activity indicating that these stromal cells have differentiated 
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(Fig. 2.3 A). ERαd/d uterine stromal cells however lack alkaline phosphatase activity indicating 
that uterine stromal cell differentiation is dependent on ERα (Fig. 2.3B).  
The second hallmark of decidualization is an up-regulation of PECAM1 indicative of 
enhanced angiogenesis. Within the uterine compartment of ERαf/f mice there is a high expression 
of PECAM1. The endothelial cells marked with this antibody have formed a vascular network 
surrounding the site of stimulation (Fig 2.3 C). In contrast, ERαd/d uterine compartment fails to 
develop this vascular network surrounding the uterine lumen (Fig. 2.3 D). Collectively, these 
results indicate that ERα plays an essential role in both stromal cell differentiation and 
angiogenesis during decidualization.  
 
ERαd/d Uteri Fail to Express PR and Other Biochemical Molecules Essential for Decidualization 
To confirm our observation that ERαd/d stromal cells fail to decidualize, we examined the 
expression of known biochemical molecules which are essential for decidualization. PR plays an 
essential role in decidualization as uteri from PR knockout mice lack the ability to decidualize in 
response to an artificial decidual stimulus (40).  While ERαf/f uterine sections show prominent 
PR expression, ERαd/d uterine stromal cells fail to express PR mRNA or protein, indicating 
compromised deciualization in absence of ERα (Fig. 2.4 B&C).  
Prolactin-related protein (PRP) is a well known marker of stromal cell decidualization 
(41). ERαd/d uterus fails to express PRP mRNA after artificial decidual stimulus. In addition, 
expression of several molecules critical for decidualization including CCAAT/enhancer binding 
protein beta (C/EBPβ), bone morphogenetic protein 2 (BMP2), and wingless-related MMTV 
integration site 4 (WNT4) are down-regulated in the ERαd/d uterus (Fig. 2.4 D) (42-43). It is 
likely that ERα is a master regulator of this cellular differentiation event.  
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Stromal ERα Expression is Critical for Decidualization 
The ERαd/d uterus has an efficient deletion of ERα in both uterine epithelial cells as well 
as stromal cells (Fig. 2.2B). The question then arises, is ERα acting directly in the uterine 
stromal cells to promote decidualization or is ERα acting within the uterine epithelial cells via an 
indirect mechanism to promote decidualization? To address this question, we employed an in 
vitro decidualization experiment. Primary uterine stromal cells were isolated directly from the 
mouse uterus and decidualized in culture after administration of E and P (43). Using this method, 
stromal cells decidualize in vitro independent of epithelial cells.   
Uterine stromal cells were isolated from ERαf/f and ERαd/d mice and cultured in presence 
of E and P. As stromal cells decidualize in culture, they take on a fibroblast morphology as seen 
with ERαf/f stromal cells after 24 and 48 hrs of culture (Fig. 2.5 A&C). ERαd/d stromal cells fail 
to take on this decidual morphology (Fig. 2.5 B&D). To confirm our observations, we quantified 
PRP mRNA expression, a marker of decidualization. In contrast to ERαf/f stromal cells, ERαd/d 
uterine stromal cells fail to express PRP mRNA levels (Fig. 2.5F). Collectively, both 
morphological and biochemical analyses indicate that ERα in uterine stroma is essential for 
decidualization.  
 
Microarray Analysis Indicates Regulation of Cell Cycle Genes by ERα 
To identify down-stream molecular targets of ERα within uterine stromal cells during 
decidualization, we employed microarray analysis.  ERαf/f and ERαd/d mice were subjected to 
artificial decidual stimulus and uterine stromal cells were isolated 10 and 24 hrs post-oil 
stimulus. RNA was isolated from these uterine stromal cells and subjected to microarray analysis 
using Affymetrix chips. Microarray data were analyzed using Panther Analyses, which indicated 
a large portion of these aberrantly regulated genes to be involved with the cell cycle (Fig. 2.6). 
Further analysis using Ingenuity Pathway Analysis indicated that canonical pathways associated 
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with polo-like kinases, essential molecules for mitosis, are aberrantly regulated in absence of 
ERα (data not shown).  
To determine if mitosis is affected during stromal cell decidualization in absence of 
ERα, ERαf/f and ERαd/d mice were subjected to artificial decidualization and uterine horns were 
collected 16 hrs post stimulus. ERαf/f stromal cells express a high level of phospho-histone 3, a 
marker of mitosis, surrounding the uterine lumen (Fig. 2.7A). ERαd/d stromal cells fail to express 
this essential mitosis marker during decidualization indicating that uterine stromal cells are 
unable to enter mitosis in absence of ERα (Fig. 2.7B).  
To determine if uterine stromal cells are able to enter the cell cycle in absence of 
ERα, we analyzed the expression of multiple cell cycle genes in stromal cells of ERαf/f and 
ERαd/d mice 10 hrs post artificial decidual stimulus. During proliferation, cells enter the G1 
phase of the cell cycle from a resting state, G0. Cells continue through the cell cycle from G1 to 
S phase, DNA replication, to G2 phase and then to mitosis, M phase, for cell replication. The cell 
cycle is tightly controlled by cyclins, cyclin-dependant kinases (Cdk), and other check-point 
molecules (44).  
The D family of cyclins as well as Cdk4 are known molecules that are essential in the 
early G1 phase of the cell cycle.  Following 10 hrs of decidualization in vivo, ERαd/d stromal 
cells express cyclins D1, D3 and Cdk4 at higher levels than ERαf/f stromal cells (Fig. 2.8A) 
indicating that these cells have the ability to enter the cell cycle in absence of ERα. However, 
expression of late G1 molecules, such as cyclin E1, Cdk2, E2F1 and E2F3, is down-regulated 
during decidualization in absence of ERα (Fig. 2.8B).  Other molecules essential for S, G2 and 
M phases of the cell cycle, cyclin B2 and Cdk6, are also down-regulated during decidualization 
in absence of ERα (Fig. 2.8C). Collectively, these data indicate that in absence of ERα, uterine 
stromal cells lack the ability to progress in the cell cycle beyond the G1 phase.   
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ERα Binding Directly to EREs Facilitates Uterine Stromal Cell Decidualization 
To identify direct down-stream targets of ERα, it is essential to know if ERα binds 
directly to EREs within genomic DNA to regulate molecular targets or if ERα binds to other 
transcription factors to regulate down-stream targets during decidualization. To understand how 
ERα elicits a transcriptional response in vivo, we subjected non-classical ERα knock-in mice 
(NERKI) to artificial decidual stimulus. ERα expressed in NERKI mice lacks the ability to bind 
directly to genomic DNA.  
Mice were subjected to artificial decidual stimulus and uterine horns were collected 72 
hours after decidual stimulus was administered. Multiple mice of ‘control’ genotypes were 
employed including wild-type (wt), homozygous ERα floxed (flox/flox), heterozygous 
ERα conditional knockouts using PR-cre (cre/+ fl/+) and heterozygous global ERα knockout 
mice (+/-). All of these control mice responded to the stimulus and developed deciduoma (Fig. 
2.9A). However ERα global knockouts (ERαKO-Chambon mouse), ERα conditional knockouts 
driven by PR-cre (cre/+ fl/fl) and NERKI animals failed to elicit a decidual response. These data 
conclude that ERα binding directly to EREs within genomic DNA regulates down-stream 
molecular targets that are essential for uterine stromal cell decidualization.  
 
Hif2α is Regulated by Estrogen during Decidualization and Angiogenesis  
We have previously uncovered the essential role that local estrogen plays in the uterus 
during decidualization and angiogenesis (24). In response to aromatase inhibitors, which prevent 
E synthesis, Hif2α is down-regulated in uterine stromal cells (Fig. 2.10). These published data 
indicate that estrogen regulates Hif2α expression during uterine angiogenesis.  
 
Spatio-temporal Localization of Hif2α in the Endometrium During Early Pregnancy 
We analysed Hif2α protein expression in pregnant uteri using a Hif2α specific antibody. 
Protein expression of Hif2α on day 4 morning of pregnancy is quite low (Fig. 2.11A). Nuclear 
localization of the protein increases in the uterine stromal cells on day 4 midnight presumably in 
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response to a nidatory surge of estrogen which is critical to initiate embryo attachment to the 
uterine luminal epithelium (Fig. 2.11B). On day 5 of pregnancy, Hif2α protein remains in the 
nucleus in a small number of stromal cells immediately surrounding the implanted embryo (Fig. 
2.11C). Uterine stromal cell nuclear expression of the Hif2α protein significantly increases on 
day 6 of pregnancy and continues through day 8 of gestation, a time in which uterine 
vascularization supports embryonic growth prior to placentation (Fig. 2.11 D-F). The spatio-
temporal localization of Hif2α indicates that this protein may play a critical role during early 
pregnancy. 
 
 
Hif2α d/d Mice are Infertile, Indicating an Essential Role of Hif2α in the Uterus during 
Pregnancy 
To study the functional role of Hif2α in the uterus during pregnancy, a conditional 
knockout mouse was created. Transgenic mice with loxp sites flanking exon 2 of the Hif2α gene, 
Hif2αf/f, were crossed with PR-cre mice. The resulting conditional knockout mouse, termed 
Hif2αd/d, showed an efficient knock-down of Hif2α mRNA in uterine stromal cells of (Fig. 
2.12).  
Hif2αd/d and Hif2αf/f female adult mice were mated with wild-type C57 male mice for a 
period of 6 months.  Hif2αf/f female mice averaged 7.89 pups per liter and 5.4 liters during the 6 
month mating period. None of the Hif2αd/d mice produced any pups, indicating they were 
infertile (Table 2.2). These data conclusively indicate an essential functional role of 
Hif2α during pregnancy.  
 
Embryos Travel into the Uterus of Hif2α d/d Mice During Pregnancy and Initiate a Decidual 
Response 
To explore the role of Hif2α in the uterus during pregnancy, Hif2αd/d and Hif2αf/f female 
adult mice were mated with wild-type C57 male mice and euthanized on different days of 
pregnancy. Prior to euthanasia on day 5 of pregnancy, Chicago blue dye was injected into the tail 
vein of female mice. Chicago blue dye travels through the vasculature into the uterus to the 
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places of highest vascularization marking an embryo within the uterus with a blue band. In both 
Hif2αd/d and Hif2αf/f mice, blue bands can be seen in the uterus on day 5 of pregnancy indicating 
that embryos are reaching the Hif2αd/d uterus (Fig. 2.13 A&B).  
Uteri were next collected from Hif2αd/d and Hif2αf/f mice on day 7 of pregnancy. Gross 
morphology indicates that the embryos in the uterus of both Hif2αd/d and Hif2αf/f mice have 
initiated a decidual response. However, deciduas in the Hif2αd/d mothers appear slightly smaller 
and less filled with blood compared to Hif2αf/f mothers (Fig. 2.13C). 
 
Embryos Attach to the Luminal Epithelium of Hif2α d/d Mice to Initiate a Decidual Response but 
Fail to Invade Through the Luminal Epithelium 
Hif2αd/d and Hif2αf/f mice were mated with wild-type C57 male mice and euthanized on 
different days of pregnancy. Embryos attach to the luminal epithelium on day 4 midnight of 
pregnancy (Fig. 2.14 B). By day 5, embryos detach from the luminal epithelium but are still able 
to initiate a decidual response (Fig. 2.14 D). On day 6 of pregnancy, embryos in Hif2αf/f uterus 
invade into the uterine stroma and the epithelium is no longer present (Fig. 2.14E). However in 
Hif2αd/d uteri, embryos are unable to invade through the luminal epithelium, which remains 
intact (Fig. 2.14F). Cytokeratin 8 immunostaining on day 5 of pregnancy marks the intact 
luminal epithelium. In contrast, embryos in Hif2αf/f uterus attach to the luminal epithelium and 
invade through these cells by disrupting epithelial cell tight junctions (Fig. 2.14 G&H).  
 
MUC1 is Down-regulated in the Hif2α d/d Uterine Luminal Epithelium, Indicating a Receptive 
State 
Mucin 1, MUC1, is a cell surface glycoprotein regulated by estrogen in the uterus (46). 
MUC1 is expressed on day 1 of pregnancy and down-regulated in the luminal epithelium on day 
4 of pregnancy indicating a receptive uterus. On days 4 and 5 of pregnancy in Hif2αd/d mice 
MUC1 is not present is the uterine epithelium (Fig. 2.15 B&D). The lack of MUC1 indicates that 
the luminal epithelium of Hif2αd/d mice is receptive to the attaching embryo.  
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Hif2α d/d Uterus has the Ability to Decidualize 
To address the role of Hif2α in the process of decidualization in the absence of an 
implanting embryo, an artificially-induced decidualization experiment was employed. The uteri 
of Hif2αd/d and Hif2αf/f mice were collected 72 hrs after a stimulus of oil was administered into 
the uterus. Histological examination clearly indicates a decidual response in both Hif2αd/d and 
Hif2αf/f uteri (Fig. 2.16 A&B). Wet weight gain data also indicate no difference in the robustness 
of the response between these two transgenic animals (Fig. 2.16C). However, qPCR analysis 
indicates a down-regulation of two critical decidual molecules, PRP and Cx43, in the Hif2αd/d 
deciduoma (Fig. 2.16D). Even though a decidual response is initiated in Hif2αd/d uterus, a lack of 
essential decidual markers indicates that without Hif2α uterine decidual cells are not fully 
functional. 
 
Decidualization in Absence of Hif2α is Initiated but Not Complete 
We next analyzed the spatial expression of decidual markers during early pregnancy. 
Two classical indicators of decidualization are an increase in alkaline phosphatase activity and 
an increase in PRP protein within decidual cells. Alkaline phosphatase activity increases by day 
5 of pregnancy, very shortly after decidualization is initiated. However, PRP protein is not 
increased until day 6 of pregnancy and is a late marker of decidualization. We chose to analyze 
these two markers to determine when decidualization is affected in the Hif2αd/d uterus. 
Alkaline phosphatase activity was assessed in uterine sections from day 7 of pregnancy 
and in uterine sections after 72 hrs of artificial decidualization. In absence of 
Hif2α, decidualization is clearly initiated as there is an increase in alkaline phosphatase activity 
on day 7 of pregnancy (Fig. 2.17D) and 72 hrs after administration of artificial stimulus (Fig. 
2.17B). Stromal cells are able to undergo differentiation program in absence of Hif2α. 
We next looked at PRP, a late decidual marker. In Hif2αf/f mice, there is an induction of 
PRP surrounding the site of stimulus 72 hrs after oil administration (Fig. 2.17E). Additionally 
during pregnancy, Hif2αf/f mice express PRP surrounding the implanted embryo (Fig. 2.17G). 
However there is a complete lack of PRP expression in the Hif2αd/d uterus either during normal 
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pregnancy or artificial decidualization (Fig. 2.17 F&H). Clearly the decidualization program is 
initiated in absence of Hif2α but fails to reach the terminal differentiated state.  
Uterine Angiogenesis in Absence of Hif2 is Impaired 
Hif2α is known to induce angiogenic responses in a number of tissues. To determine if 
the Hif2αd/d uterus has the ability to form angiogenic networks during decidualization, we mated 
Hif2αf/f and Hif2αd/d mice to C57 wild-type males and collected uterine horns on day 7 of 
pregnancy. Immunohistochemistry was completed on these uterine samples using anti-PECAM1 
antibody, a marker of endothelial cells.  On day 7 of pregnancy, the Hif2αf/f uterus forms a 
robust angiogenic network of endothelial cells surrounding the implanted embryo (Fig. 2.18 A). 
The Hif2αd/d uterus shows a blunted expression of PECAM1 indicating a defect in angiogenesis 
(Fig. 2.18 B). These data indicate that Hif2α plays an essential role in angiogenesis during 
decidualization.  
 
2.4- Discussion 
 According to the New York Department of Health, 7.1 percent of married couples in the 
United States are infertile. Of the 6 million pregnancies that do occur in the United States, one-
third will result in pregnancy loss. Many couples turn to assisted reproductive techniques such as 
IVF to circumvent infertility issues. Because IVF procedures result in live birth 40-60% of the 
time, often more than one embryo are transferred to the mother’s womb. This may result in 
multiple live births which can be monetarily, emotionally and physically burdensome to parents. 
Understanding implantation failure at the molecular level will facilitate the development of 
treatments and procedures for infertile women. These treatments will increase the success rate of 
IVF and decrease the chance of unwanted multiple births from this procedure.  
 By employing the ERαd/d mouse model, we addressed the essential role of ERα in uterine 
stromal cells. Previous published studies from our laboratory indicate that local E production by 
uterine stromal cells is essential to facilitate decidualization (24). This local E acts via ERα to 
promote stromal cell decidualization. Successful decidualization is absolutely critical for embryo 
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implantation and identification of down-stream targets of ERα is essential to understand cellular 
events during this process.  
In the absence of ERα, uterine stromal cells are unable to differentiate, as shown by the 
lack of alkaline phosphatase activity and PRP mRNA expression. Furthermore in absence of 
ERα, uterine stromal cells are unable to express molecules essential for decidualization such as 
PR, C/EBPβ, BMP2 and WNT4. To identify molecular pathways driven by ERα during 
decidualization, we employed microarray analysis. This analysis indicates a defect in uterine 
stromal cell proliferation in absence of ERα. Following up these analyses, molecules essential 
for cell cycle progression were analyzed in ERαd/d uterine stromal cells post decidual stimulus.  
ERαd/d uterine stromal cells lack phopho-histone 3 after decidual stimulus. However, early G1 
phase molecules, such as cyclin D1 and D3 remain intact. These results indicate that uterine 
stromal cells lacking ERα fail to fully proliferate but appear to be able to enter the cell cycle.  
  To further address the role of ERα in stroma proliferation and differentiation, we 
employed the NERKI mice. These studies indicate that ERα binds directly to genomic DNA to 
elicit these cellular responses. Further work to identify essential molecular targets of ERα 
containing ERE sequences within their promoters will be necessary to fully understand how ERα 
regulates stromal cell decidualization.  
In addition to compromised stromal differentiation, ERαd/d mice exhibit a defect in 
angiogenesis. Angiogensis of the decidua is absolutely necessary to bring essential maternal 
nutrients to the developing embryo prior to placentation. Our laboratory has identified multiple 
molecules regulated by E that are critical for angiogenesis during decidualization including 
hypoxia-inducible factor 2 alpha (Hif2a), angiopoietin 2 (Ang2), and connexin 43 (Cx43) (24-
25). These findings warrant further studies on the molecular mechanisms of E signaling to 
promote angiogensis during early pregnancy.  
We have previously identified stromal cell production of estrogen as an essential driver 
of decidualization and angiogenesis in the uterus. By inhibiting estrogen production with an 
aromatase inhibitor, we know that this local estrogen regulates key molecules of decidualization, 
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such as alkaline phosphatase, PRP, and BMP2. Additionally local estrogen regulates other 
molecules, Hif2α and Ang2, which have been previously published in other systems to regulate 
angiogenic responses. Therefore, we hypothesized that estrogen regulates Hif2α to mediate 
angiogenesis in the uterus. To test the function of hif2α we created a conditional knockout 
mouse model, Hif2αd/d mouse.  
 Even though Hif2αd/d mice ovulate, they are completely infertile. Surprisingly, we found 
that embryos attach to Hif2αd/d luminal epithelium but are unable to penetrate through the 
luminal epithelial cells. However embryos flushed from Hif2αd/d uteri on day 4 and transferred 
into wild-type mothers will successfully develop to term (data not shown). Therefore the 
embryos within Hif2αd/d pregnant mice have the ability to penetrate through the luminal 
epithelial cells. Furthermore Hif2αd/d stromal cells are able to enter the differentiation program 
as marked by alkaline phosphatase activity following embryo attachment to the luminal epithelial 
cells. We believe that this is the first animal model to show embryo attachment, and not embryo 
invasion, as the catalyst for stromal cell decidualization in rodents.  
 Two possibilities remain to explain why embryos are unable to invade through luminal 
epithelial cells. Hif2α within luminal epithelial cells could be critical for the disassembly of 
epithelial cells during implantation. Alternatively Hif2α within stromal cells could regulate some 
factor X which acts on the epithelial cells to promote epithelial cell disassembly during 
implantation. While both of these possibilities exist, we favor the second possibility. Our 
immunohistochemical studies indicate nuclear expression of Hif2α beginning on day 4 midnight 
when the embryo attaches to the luminal epithelium. Nuclear expression remains in the stromal 
cells during decidualization. While Hif2α is expressed in the luminal epithelium on day 4 
morning, the location of this protein is always cytoplasmic in the epithelial cells. Hif2α must be 
present in the nucleus to act as a transcription factor. However, to clearly address the role of 
Hif2α within luminal epithelial cells we are creating a conditional knockout of Hif2α in luminal 
epithelial cells by employing a mouse expressing cre-recombinase driven by the Wnt7a 
promoter. Breeding studies with these epithelial cell conditional knockout mice will address the 
role of Hif2α in uterine luminal epithelial cells during implantation.  
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 It is quite remarkable that Hif2αd/d stromal cells are able to begin decidualization even 
though the embryo does not come into contact with the stromal cells. Stromal cell expression of 
alkaline phosphatase activity is unaltered in the Hif2αd/d uterus and uterine wet weight gain is 
statistically the same as Hif2αf/f mice 72 hours after artificial decidual stimulus. However, 
Hif2αd/d decidual cells do not express PRP, a classic decidualization marker which is induced 
beginning on day 7 of pregnancy. This is an indication that Hif2αd/d stromal cells are unable to 
fully differentiate and may never reach a terminal differentiated status.  
 We began to study Hif2α function in the uterus with the hypothesis that this transcription 
factor mediates angiogenesis within the uterus. As marked by PECAM1, we can see that 
angiogenesis is impaired in Hif2αd/d mice on day 7 of pregnancy. It will be imperative to identify 
the downstream molecular pathways of Hif2α during stromal cell decidualization. As a first step 
towards that goal we have isolated mRNA from stromal cells on day 5 morning of pregnancy 
from Hif2αf/f and Hif2αd/d mice and subjected this mRNA to Affymetrix microarray studies. 
Analysis of these data will help to identify the downstream molecular targets of Hif2α that are 
important for uterine stromal cell differentiation and angiogenesis.  
 
2.5- Materials and Methods 
Animals and Tissue Collection 
All animals were maintained in University of Illinois animal facilities. The health of the animals 
was monitored by Division of Animal Resources veterinarians. All procedures involving the use 
of animals were approved by the University IACUC committee. Hif2α floxed mice were 
obtained from Jax Laboratories. Transgenic female mice were mated to mature C57 wild-type 
males. The copulatory plug indicates day 1 of pregnancy. Female mice were then subsequently 
euthanized by carbon dioxide overdose on different days of pregnancy. The uterus was collected 
and either fixed in 10% buffered formalin for paraffin blocks, frozen or used to isolate stromal 
cells. 
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Artificial Decidualization 
Decidualization was artificially induced as previously described (25). Mice were ovariectomized 
and rested for 2 weeks to remove circulating hormones. Animals then were injected with 100 ng 
estrogen in 0.1ml corn oil s.c. daily for three days and then rested for two days. Following rest, 
mice were injected with E (10 ng) and P (2 mg) in 0.1ml corn oil for three days. On the third day 
of E+P injection mice were anesthetized and corn oil was injected into 1 uterine horn. Mice were 
then injected daily with E+P until mice were euthanized.  
Uterine Stromal Cell Isolation 
Uterine stromal cells were isolated as previously described (43). Briefly, uteri were removed 
from mice after euthanasia with carbon dioxide. The uterus was cut open and digested with 6 
g/liter dispase (Invitrogen) and 25g/liter pancreatin for 1hr at room temp. The enzymes were 
quenched with 10% FBS and cells were washed with Hanks balanced salt solution (HBSS). Cells 
were then incubated in 0.5 g/liter collagenase in HBSS for 1hr at 370C. After incubation the 
tubes were vortexed for 10-12 s until the supernatant became turbid with dispersed cells. The 
contents of the tube were then passed through a 80-µm gauze filter (Millipore). Cells were 
resuspended in Dulbeccos modified Eagle's medium-F12 medium (DMEM-F12; with 100 
unit/liter penicillin, 0.1 g/liter streptomycin, 1.25 mg/liter fungizone) containing 10% heat-
inactivated fetal calf serum and live cells were assessed by trypan blue staining using a 
hemocytometer. 
Immunohistochemistry 
Immunohistochemistry was carried out as previously described (25). Paraffin embedded sections 
were used. Briefly, uterine sections were blocked for 1 hr at room temp with serum. Sections 
were then incubated with primary antibodies against ERα (Novacastra), PECAM (BD), PR 
(Dako), phospho-histone 3 (Upstate), PRP (Milipore) or Hif2α (Novus Biologicals) overnight at 
40C. Sections were then incubated with biotinylated secondary antibodies at room temperature 
followed by incubation with horseradish peroxidase-conjugated streptavidin (Invitrogen). The 
sections were stained in AEC solution until optimal signal was obtained.  
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Alkaline Phosphatase Activity Assay 
The protocol for detecting alkaline phosphatase activity was followed as previously published 
(45). Briefly, frozen uterine sections were incubated in the dark at 370C for 60 mins in 2mM α-
napthyl phosphate. The uterine alkaline phosphatase activity releases orthophosphate and napthol 
derivatives from the stubstrate. The napthol derivatives are simultaneously coupled with 
diazonium salk present in the incubating medium to form a dark dye marking the site of enzyme 
action. To terminate the enzymatic reaction, the tissue sections were rinsed in water. 
Quantitative PCR and RNA Isolation 
RNA was isolated from tissues or cells using trizol followed by RNA cleanup kit (Qiagen). RNA 
was converted to cDNA using a kit (Applied Biosystems). Oligonucleoties specific for genes of 
interest were developed. QPCR reaction was carried out using SYBR-Green master mix 
(Applied Biosystems) on either 7000 or 7500 Applied Biosystems Real-time PCR machines.   
Microarray Analysis 
Mice were subjected to artificial decidualization and uterine stromal cells were isolated 10 and 
24 hrs post-stimulus. Messenger RNA was isolated from cells using trizol and purified using a 
Qiagen kit. Messenger RNA was submitted to the Keck Biotechnology Center at UIUC and 
hybridization on Affymetrix chips was performed. Data were analyzed using Panther and 
Ingenuity Pathway Analysis software.  
 
 
 
 
 
 
 
  
 
 
 
26 
 
2.6- Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 – ERα Protein Localization in the Mouse Uterus During Early Pregnancy. 
Stromal cell localization of the ERα protein is present on Day 1 (A) and Day 4 (B). 
ERα expression in the stromal compartment persists on Day 5 (C), the beginning time point 
of stromal cell differentiation. 
2.1: ERα Protein Localization in the Mouse Uterus During Early Pregnancy. 
day 1 ( ) and day 4 (B). 
day 5 ( ), the beginning ti e point 
Red indicates ERα protein expression. Blue is hemotoxylin 
marking the nucleus of all cells.   
Fig. 2.2: ERαd/d Mice Fail to Display a Decidual Response After Artificial 
Decidual Stimulus Administration. Uterine cross sections from ERαf/f and ERαd/d 
mice were subjected to immunohistochemistry using anti-ERα.  ERαd/d mice display 
efficient deletion of ERα (B) when compared to ERαf/f control mice (A). ERαf/f and 
ERαd/d mice were subjected to an artificial decidual stimulus. Uteri were collected 
72 hours after administration of oil stimulus. ERαd/d uteri fail to give a decidual 
response (C). 
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Table 2.1: ERαd/d Mice are Infertile. ERαd/d and ERαf/f female mice were 
mated with C57 wild-type male mice for a period of 6 months. ERαf/f female 
mice averaged 7.5 pups per litter and 2.8 liters per female. ERαd/d female mice 
are completely infertile as they did not give any pups over the 6 month breeding 
period.  ERαd/d and ERαf/f immature female mice will ovulate similar number of 
oocytes when stimulated with exogenous gonadotropins. However after ERαd/d 
female mice reach maturity they will no longer ovulate upon super-ovulation.   
  
 
 
 
28 
 
 
                                                                                                                             
 
 
 
 
 
 
 
 
Alkaline  
Phosphatase 
PECAM-1 
ERα f/f 
ERα d/d 
A 
B
C 
D 
Fig. 2.3: ERαd/d Uteri Fail to Decidualize upon Artificial Stimulation. ERαd/d 
and ERαf/f uteri were subjected to artificial decidualization and collected 72 hrs 
after administration of stimulus. Stromal cells in the ERαf/f uterus undergo 
differentiation following stimulation as marked by alkaline phosphatase (A). 
ERαd/d uterine stromal cells fail to undergo differentiation and are absent for 
alkaline phosphatase activity (B). Another hallmark of decidualization is the 
formation of angiogenic networks surrounding the embryo or site of stimulus. 
ERαf/f uteri display a vast angiogenic network surrounding the site of stimulus as 
marked by PECAM-1, an endothelial cell marker (C). Although ERαd/d uteri do 
have endothelial cells present it is clear that these endothelial cells have not 
organized into vessels (D). The ERαd/d uterus was unable to decidualize. 
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Fig. 2.4: ERαd/d Uteri Fail to Express PR and Other Genes Known to Play an 
Essential Role in Decidualization. ERαd/d and ERαf/f uteri were subjected to artificial 
decidualization and collected 72 hrs after administration of stimulus. 
Immunohistochemistry indicates a high level of PR protein in the decidua of ERαf/f uterus 
(A). ERαd/d uterus fails to express PR protein following decidual stimulation (B). ERαd/d 
uterus also fails to express PR mRNA after decidual stimulation (C). Furthermore, ERαd/d 
uterus also fails to express genes known to play an essential role in decidualization such as 
PRP, C/EBPβ, BMP2 and WNT4 as measured by quantitative PCR (D).   
ERαf/f ERαd/d 
  
 
 
 
30 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
24 48 72 96
R
e
la
ti
v
e
 m
R
N
A
 E
xp
re
ss
io
n
PRP Expression in ERa d/d Cells 
During in Vitro Decidualization
ERa fl/fl
ERa d/d
ERα f/f ERα d/d 
24 hr 
48 hr 
A B 
C D 
E 
Fig. 2.5: ERαd/d Uterine Stromal Cells Fail to 
Differentiate in vitro in Absence of Luminal Epithelial 
Cells. Uterine stromal cells are enzymatically isolated from 
ERαd/d and ERαf/f female adult mice. ERαd/d and ERαf/f 
uterine stromal cells are cultured for 24hrs (A&B) and 
48hrs (C&D) in the presence of estrogen and progesterone. 
ERαd/d uterine stromal cells do not express essential levels 
of PRP and fail to differentiate (E). * indicates a significant 
difference in gene expression between mice with different 
genetic backgrounds at a p-value cutoff of 0.05 using a 
student’s t-test.  
f/f 
* * 
* * 
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Fig 2.6: Microarray Analysis Indicates that ERαd/d Uterine Stromal Cells Display 
Aberrant Expression of Multiple Cell Cycle Molecules. ERαd/d and ERαf/f female adult 
mice are given a decidual stimuls. Mice are euthanized 10hrs post stimulus, uterine stromal 
cells are isolated, mRNA is isolated from the stromal cells and subjected to Affymetrix 
microarray analysis. Panther analysis of aberrantly regulated genes suggests that ERαd/d 
uterine stromal cells aberrantly express a number of cell cycle molecules post stimuls when 
compared to ERαf/f uterine stromal cells. 
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Fig 2.7: ERαd/d Uterine Stromal Cells Fail to Undergo Mitosis Following 
Artificial Stimulus. ERαd/d and ERαf/f female adult mice are given a decidual 
stimulus and euthanized 16hrs post stimulus. Uterine cross sections are stained for 
phospho-Histone 3, a marker of mitosis. ERαf/f uterus completes mitosis following 
artificial stimulus (A). ERαf/f uterus fails to proliferate following artificial stimulus 
(B).  
A B 
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Fig. 2.8: ERαd/d Uterine Stromal Cells Fail to Transition from G1 to S Phase 
Following Artificial Stimulus. ERαd/d and ERαf/f female adult mice are given a 
decidual stimulus and euthanized 10hrs post stimulus, stromal cells are isolated and 
mRNA is extracted. QPCR is employed to measure mRNA levels of cell cycle 
regulatory genes. ERαd/d uterine stromal cells express adequate levels of early G1 cell 
cycle genes (A). However ERαd/d uterine stromal cells do not express adequate levels 
of cell cycle molecules reqired for late G1, S, G2 or M phase (B&C).  * indicates a 
significant difference in gene expression between mice with different genetic 
backgrounds at a p-value cutoff of 0.05 using a student’s t-test.  
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Fig. 2.9: Decidualization Requires ERα to Bind to EREs for Transcription of Down-
stream Genes. Mice are subjected to artificial decidualization and euthanized 72hrs post 
stimulation. Mice with intact ERα are able to illicit a decidual response. Mice with ERα 
knocked out in every cell, ERαKO, or specifically in the uterus, ERαd/d, are unable to 
form deciduomas. Furthermore mice with ERα unable to bind to EREs in the genome, 
NERKI, are also unable to form deciduomas (A). Uterine wet weight gain for each mouse 
genotype are depicted in B. Clearly ERα transcription via EREs is required for 
decidualization. 
ERαd/d 
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Fig. 2.10: Hif2α is Down-regulated in Presence of Aromatase Inhibitor 
during In Vitro Decidualization. Identification of angiogenic factors regulated 
by intrauterine E during decidualization. Stromal cells isolated from uteri of d 4 
pregnant mice were subjected to in vitro decidualization in the presence or 
absence of letrozole for 72 h. RNA was prepared from these cells and subjected 
to real-time PCR analysis using gene-specific primers.  
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Fig. 2.11: Hif2α Protein Localization in the Mouse Uterus During Early 
Pregnancy. Expression of Hif2α remains low on day 4 morning of pregnancy (A) 
However nuclear expression of Hif2α increases by day 4 midnight (B) in uterine 
stromal cells.  On day 5 of pregnancy nuclear expression only remains in a small 
number of stromal cells immediately surrounding the implanted embryo (C). 
Protein expression greatly increases on day 6 of pregnancy in differentiated and 
undifferentiated stromal cells (E). Protein expression remains high through day 8 of 
pregnancy and is localized to uterine stromal cells surrounding uterine vasculature 
(F). Black arrows indicate nuclear location of Hif2α. 
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Table 2.2: Hif2αd/d Mice are Infertile. Hif2αd/d and Hif2αf/f female mice are mated 
with C57 wild-type male mice for a period of 6 months. Hif2αf/f female mice averaged 
7.9 pups per litter and 5.4 liters per female. Hif2αd/d female mice are completely 
infertile as they did not give any pups over the 6 month breeding period.   
   Hif2α /f    Hif2αd/d 
Fig. 2.12: Hif2αd/d Mice have Efficient Knockdown of Hif2α. Hif2αd/d and Hif2αf/f 
female mice are mated with C57 wild-type male mice and uterine stromal cells are 
collected on day 4 at midnight and mRNA is isolated. Quantitative PCR indicates an 
80% reduction of Hif2α in uterine stromal cells of Hif2αd/d female mice compared to 
Hif2αf/f control.  * indicates a significant difference in Hif2α gene expression between 
Hif2αf/f mice and Hif2αd/d mice using a p-value cutoff of 0.05. Student’s t-test was used 
to determine statistical significance.  
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Fig. 2.13: Hif2αd/d Uterus Has 
the Ability to Vascularize and 
Decidualize During the Early 
Stages of Pregnancy. Blue dye is 
injected into the tail vein of 
anesthetized mice on day 5 
morning of pregnancy.  Black 
arrows point to blue dye indicating 
embryos in the uterus of Hif2αf/f 
(A) and Hif2αd/d (B) female mice. 
Mice are euthanized on day 7 of 
pregnancy and the uterus is 
removed. Hif2αf/f and Hif2αd/d  
uteri appear to decidualize during 
pregnancy (C). 
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Fig. 2.14: Embryos Fail 
to Invade Through the 
Luminal Epithelium in 
the Hif2αd/d Uterus 
During Pregnancy. 
Hif2αf/f and Hif2αd/d 
female mice are mated to 
C57 wild-type male mice 
and euthanized on days 4, 
5 and 6 of pregnancy. 
Embryos attach to the 
luminal epithelium of both 
Hif2αf/f (A) and Hif2αd/d 
(B) uteri on day 4 
midnight of pregnancy. 
The embryo tightly 
adheres to the luminal 
epithelium of Hif2αf/f (C) 
mice but detaches from 
the luminal epithelium of 
Hif2αd/d (D) female mice 
on day 5 morning of 
pregnancy. Embryos 
invade through the 
luminal epithelium of 
Hif2αf/f mice by day 6 
morning (E). Embryos are 
unable to invade through 
the luminal epithelium of 
Hif2αd/d female mice, die 
and become resorpbed. 
Cytokeratin 8 marks the 
luminal epithelial cells in 
the Hif2αf/f uterus after 
the embryo invades on 
day 5 morning of 
pregnancy. The luminal 
epithelial cells of the 
Hif2αd/d remain intact on 
day 5 morning of 
pregnancy.  
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Fig. 2.15: Hif2αd/d Uterine Luminal Epithelium is in a Receptive State During Days 4 
and 5 of Pregnancy. Hif2αf/f and Hif2αd/d female mice are mated to C57 wild-type male 
mice and euthanized on days 4 and 5 pregnancy. The uterine luminal epithelium of Hif2αf/f 
(A&C) and Hif2αd/d (B&D) mice on day 4 midnight and day 5 morning of pregnancy fails 
to express MUC1 indicating a receptive state. A uterine cross section of day 1 of pregnancy 
provides a positive control for MUC1 immunohistochemistry (E).  
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Fig. 2.16: Hif2αd/d Uteri Gain Wet Weight after Artifical Decidual Stimulus but Fail 
to Express Essential Decidual Genes. Hif2αf/f and Hif2αd/d female mice are subjected 
to artificial decidual stimulus and euthanized 72hrs post stimulation. Hemotoxylin and 
Eosin staining indicate decidual response in both Hif2αf/f (A) and Hif2αd/d (B) mice. 
Uterine wet weight gain does not statistically differ (p= .44) between Hif2αf/f and 
Hif2αd/d mice after decidual stimulus (C). Despite wet weight gain Hif2αd/d uterine 
stromal cells fail to express essential levels of PRP and Cx43 mRNA, two well known 
markers of decidualization (D).  
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Fig. 2.17: Hif2αd/d Uteri Fail to Fully and Functionally Decidualize. Hif2αf/f and Hif2αd/d 
female mice are subjected to artificial decidual stimulus and euthanized 72hrs post stimulation. 
Hif2αf/f and Hif2αd/d female mice are mated to C57 wild-type mice and euthanized on days 6 
and 7 of pregnancy. Hif2αf/f uterus displays alkaline phosphatase activity 72 hrs post artificial 
stimulus (A) and on Day 7 of pregnancy (C) indicating that uterine stromal cells have begun to 
differentiate into decidual cells. Hif2αd/d uterus also displays alkaline phosphatase activity 72 
hrs post artificial stimulus (E) and on Day 6 of pregnancy (G) indicating that uterine stromal 
cells have fully differentiated into decidual cells. Hif2αd/d uterus fails to expresses PRP protein 
72 hrs post artificial stimulus (F) and on Day 6 of pregnancy (H) indicating that Hif2αd/d 
uterine stromal cells do not have the ability to fully differentiate into decidual cells. 
Hif2αf/f Hif2α
d/d 
72 hrs ADR—alkaline phosphatase 
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Fig. 2.18: Hif2αd/d within the Uterine Stromal Cells is Essential for Angiogenesis during 
Decidualization. Hif2αf/f and Hif2αd/d female mice are mated to C57 wild-type mice and 
euthanized on day 7 of pregnancy. Hif2αf/f uterus expresses a high level of PECAM1 staining 
marking endothelial cells (A 10x & B 4x). These endothelial cells form a vascular network 
surrounding the implanted embryo. Hif2αd/d uterus shows a decrease in PECAM1 staining 
compared to the Hif2αf/f uterus (B 10x & D 4x). Hif2αd/d uterus fails to form vascular networks 
surrounding the implanted embryo. 
 
  
 
 
 
44 
 
 
 
 
 
 
 
 
 
Part II: The Role of Estrogen Receptor Alpha in the Ovary During Ovarian Tumorigenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
45 
 
CHAPTER 3: Literature Review - Part II 
3.1 Ovarian Cancer 
 Approximately 14,000 women died from ovarian cancer in 2010 in the United States, 
making ovarian cancer one of the top five types of cancer to cause deaths in women (47). The 
risk of ovarian cancer increases exponentially with age but plateaus between age 50 to 55. A 
global perspective on cancer statistics indicates there is not much difference in ovarian cancer 
risk between developed and non-developed nations. There is a cumulative life-time risk of 1% 
for women to be diagnosed in developed nations, whereas women in developing nations 
experience a 0.5% life time risk (48).  
 Several factors contribute to the risk associated with ovarian cancer. Women who bare 
children experience a 40% reduction in ovarian cancer risk (49). This could be associated with 
the reduction in lifetime ovulation events. Women who take oral contraceptives also experience a 
decreased risk of ovarian cancer. A meta-analysis of 45 studies concluded that for each 5 years 
of oral contraceptive use a woman reduces her risk of ovarian cancer by 20% (50). This 
reduction in ovarian cancer risk is thought to be associated with increased periods of 
anovulation.  Some investigators believe that epithelial ovarian cancer cells are derived from 
germinal inclusion cysts which are thought to form after ovulation by entrapping part of the 
epithelium below the healing surface of the ovary. However, there is not concrete evidence that 
the prevalence of germinal inclusion cysts correlates to oral contraceptive use (51). The 
protective aspect of pregnancy and oral contraception use remains a mystery.  
 About 15% of ovarian cancer patients report a positive family history of the disease. The 
discovery of mutations within the breast cancer 1, early onset (BRCA1) gene and breast cancer 
2, early onset (BRCA2) gene has been directly correlated with familial history of breast cancer. 
These are tumor suppressor genes and genetic mutations have been shown to increase a woman’s 
chance of breast cancer by 9- to 36-fold. It was later found that women with these genetic 
mutations also have a 6- to 61-fold increase risk for ovarian cancer (52). Today, screening for 
BRCA1/2 mutations allows women to elect to have surgeries such as oophorectomy to reduce 
the chance of ovarian cancer.  
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 Mutations in tumor suppressor genes are frequently seen in a variety of tumor cases. 
Mutations in the p53 gene are common among invasive epithelial ovarian tumors.  A mutation in 
this gene is thought to impair the ability of p53 to recognize damaged DNA preventing induction 
of the normal apoptotic pathway for self-destruction. Studies have indicated that p53 function is 
lost in 15% of early-stage carcinomas and 50% of late-stage carcinomas, indicating that this 
mutation may be a late event in tumorigenesis resulting in highly aggressive cancers (53).  
   Women diagnosed with ovarian cancer have a very low 5-year survival rate. The 
majority of women are diagnosed with this disease after metastasis to the peritoneum. Women 
with ovarian tumors usually experience vague clinical symptoms such as bloating or problems 
with digestion. Detecting ovarian cancer is difficult for clinicians as there are no reliable 
diagnostic tools. Clinicians have used CA125, an epithelial antigen secreted into the blood, for 
the past 25 years to diagnosis ovarian cancers. However, the normal serum level of CA125 varies 
dramatically from patient to patient and often results in false-positive diagnosis of ovarian 
cancers (54). Undoubtedly, there is a great need to discover dependable diagnostic markers for 
early stage ovarian cancers.  
 
3.2 Types of Epithelial Ovarian Cancer 
 Over 90% of the ovarian cancer cases are epithelial cell in nature. Germ cell and sex-cord 
stromal tumors make up the rest of ovarian cancers. Malignant germ cell tumors are quite rare 
and are most common in adolescents (55). Malignant sex-cord tumors, which account for about 
5% of cancer cases, are more closely related to epithelial ovarian tumors as they are more 
commonly seen in older women (56). As the vast majority of ovarian cancers are derived from 
epithelial cells, the different histological types of epithelial ovarian cancer will be reviewed 
briefly.  
  Epithelial ovarian cancers are characterized into four main types based on their 
histology. The most frequent type is serous ovarian cancer accounting for approximately 50%-
70% of all epithelial ovarian cancers. Serous epithelial cancer cells resemble the epithelial cells 
of the Fallopian tube. Based on genetic profiling serous cancers have been separated into two 
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types, high and low grade. The high grade serous cancers are far more aggressive than the low 
grade and are characterized by p53 mutations (57).  
 Endometrioid epithelial ovarian cancer accounts for 15-20% of epithelial ovarian cancer 
cases and histologically resembles the endometrium. Mutations of CTNNB1, the gene encoding 
β-catenin, seem to be unique to these types of cancers (58).  
 Mucinous epithelial ovarian cancer is less frequently diagnosed and accounts for 
approximately 5-10% of all epithelial ovarian cancers (59). These tumors secrete mucin. The 
epithelial cancer cells are thought to resemble that of the endocervix.  
 Accounting for less than 5% of all epithelial ovarian cancers are clear cell tumors and 
mixed tumors (60). Clear cell tumors have epithelial cells that are thought to resemble that of the 
gestational endometrium. Mixed tumors are those which develop characteristics of two or more 
of the other defined histotypes of epithelial ovarian cancer and are extremely rare.  
 
3.3 Transgenic Mouse Models of Epithelial Ovarian Cancer 
 A lack of sufficient animal models to study the etiology of epithelial ovarian cancer has 
hindered the development of better diagnostic tools and treatments for epithelial ovarian cancer. 
Animal models that manifest a pathophysiology similar to humans can be used to better 
understand specific diseases. Through the use of transgenic mouse models we can identify 
molecular players that drive a specific pathophysiology. A brief overview of transgenic mouse 
models that have previously been generated to study epithelial ovarian cancer is outlined below. 
 Orsulic et al. was perhaps the first to develop a transgenic mouse model for ovarian 
epithelial cancer by using transgenic animals that expressed the TVA virus receptor driven by the 
keratin 5 promoter to target epithelial cells (61). Development of this animal model allowed 
investigators to better understand the role of oncogenes, c-myc, kras, and AKT, in epithelial 
ovarian cancer in vivo. However, because the keratin 5 promoter targets epithelial cells from 
multiple organs, ovaries were infected in culture and then transplanted back into recipient mice. 
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Ovarian transplant procedures are difficult and time consuming. Thus this may not be an 
efficient experimental model to use, although these initial studies developed some of our earlier 
understanding of epithelial ovarian cancer in vivo.  
 Another model used to understand epithelial ovarian cancer was developed by Connolly 
et al. who targeted simian virus 40 T antigen (SV40 TAg) to the epithelial ovarian surface by 
using the mullerian inhibitory substance type II receptor (MISIIR) promoter (62). Approximately 
50% of female mice developed ovarian tumors that mimicked histology of the serous type. 
However, these mice die between 6-13 weeks of age and are infertile, making it almost 
impossible to establish a permanent line of transgenic animals. Furthermore, these animals 
develop extremely aggressive tumors early in life which does not mimic what is seen in women.  
 To develop an animal model that more accurately represents human ovarian cancer, 
Flesken-Nikitin et al. developed a novel experimental technique to understand the function of 
tumor suppressor genes, in this case p53 and Rb (63). Mice which have loxp sites inserted into a 
gene of interest were used in these experiments. Deletion of the specific gene within the ovarian 
epithelial cells was obtained by injecting adenoviruses, which express cre recombinase (Cre) 
driven by the cytomegalovirus (CMV) promoter, under the bursa of the ovary. This experimental 
technique has been picked up by several laboratories to generate mouse models.  
 Since the work of Connolly et al. and Flesken-Nikitin et al., several laboratories have 
generated other animal models by utilizing the conditional knockout system. Wu et al. used this 
technique to knock-down PTEN and adenomatous polyposis coli (APC) expressed in the OSE. 
These transgenic mice form tumors that specifically mimic ovarian endometrioid 
adenocarcinomas (64). Perhaps the most recent generation of a mouse model is by Joanne 
Richard’s laboratory (65). This model uses the MISIIR promoter to drive excision of the PTEN 
and KRAS genes. This animal model forms serous ovarian carcinomas.  
 The past decade has brought new insight to the understanding of ovarian epithelial 
tumorigenesis in vivo. However many of these animal models develop very aggressive tumors 
early in life. This does not reflect the physiology of ovarian tumor progression in women because 
ovarian cancer is far more frequently diagnosed in older post-menopausal women.  Furthermore 
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administration of cre recombinase by intra-bursal adenovirus administration may result in 
observations that deviate from the pathology seen in humans (66). Caution should be taken when 
developing or using these developed animal models to study ovarian epithelial tumorigenesis.  
 
3.4 Estrogen and Epithelial Ovarian Cancer 
 The role of estrogen in breast tumorigenesis has long been established. Today women 
with breast cancer are often treated with aromatase inhibitors or estrogen receptor antagonists to 
effectively treat breast cancer. However, the role of estrogen in ovarian cancer remains less clear.  
 Several epidemiological studies have shown that post-menopausal women receiving 
hormone replacement therapies have an increased risk of ovarian cancer (67-70). Both estrogen 
or estrogen plus progesterone hormone replacement therapies are known to increase a woman’s 
risk. However women of reproductive age taking hormones as oral contraceptives have a 
decreased risk of ovarian cancer. This may seem paradoxical at first but post-menopausal women 
have very high levels of other circulating hormones such as FSH and LH. These epidemiological 
data may indicate that ovarian tumorigenesis is driven by estrogen in combination with high 
levels of FSH and/or LH.  
 Three phase II studies have been carried out testing the effectiveness of letrozole, an 
aromatase inhibitor, as a treatment for ovarian cancer. Collectively, these studies indicate that a 
population of women would benefit from letrozole treatment. Phase II trial for ovarian cancer 
treatment studies enroll women who have stage III or IV cancer because the lack of diagnostic 
techniques limits enrolling many women with stage I or II cancer. Letrozole may inhibit ovarian 
tumorigenesis in early stages but studies have not clearly addressed this possibility.  
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3.5 Specific Aims 
Recently a transgenic mouse model was developed in the lab. This mouse model lacks 
expression of ERα within the pituitary resulting in a lack of negative estrogen feedback on the 
hypothalamus-pituitary-ovarian axis. Furthermore, this conditional knockout mouse model, 
termed ERαd/d, maintains ERα within the ovary and over-expresses aromatase in the ovary. 
These phenotypes result in high circulating levels of E, P, luteinizing hormone (LH) and 
testosterone (T).  Based on these observations we formulated the following aim: 
Aim 3. To investigate the role of estrogen acting via ERα in the formation of ovarian epithelial 
tumors. 
Determine the efficiency of letrozole, an aromatase inhibitor, in blocking ovarian 
tumorigenesis.  
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CHAPTER 4: The Role of Estrogen Receptor Alpha in the Ovary During Ovarian 
Tumorigenesis 
4.1- Abstract 
The etiology of ovarian cancer is poorly understood, mainly due to the lack of an appropriate 
experimental model for studying the onset and progression of this disease. Recently we have 
developed a mouse model in which aberrant estrogen receptor alpha (ERα) signaling in the 
hypothalamo-pituitary-ovarian axis leads to ovarian tumorigenesis. In this mouse model, termed 
ERαd/d, a conditional deletion of ERα gene occurred in the anterior pituitary, but ERα expression 
remained intact in the hypothalamus and the ovary. Selective ablation of ERα in the pituitary 
created a systemic hormonal imbalance in these mice. Loss of the negative-feedback regulation 
of estrogen (E) in the pituitary led to elevated levels of LH. LH hyperstimulation of ovarian cells 
resulted in elevated steroidogenic activities, leading to high circulating levels of E (64 pg/ml), P 
(9 ng/ml), LH (2.3ng/ml), and T (395 ng/ml). The ERαd/d mice exhibited formation of ovarian 
tumors with 100% penetrance, starting at 5 months of age. These tumors grew to about 11 mm in 
size by 8 months of age and most mice died by 11-12 months. Immunohistochemical analyses 
revealed that the cells within the ovarian tumors of ERαd/d mice are characterized by intense 
expression of cytokeratin 8 and 19 as well as nuclear staining of Wilms tumor 1, a well known 
marker of ovarian tumorigenesis, and paired homeobox 8 (PAX8), a marker of serous ovarian 
tumors. We investigated the ovarian cellular localization of E production. Aromatase expression 
was 16-fold higher in ovarian tumors compared to normal ovaries and was found to be expressed 
by the ovarian interstitial cells. Since E is known to drive ovarian tumorigenesis in other organs 
such as the breast, we treated mice with letrozole, an aromatase inhibitor. Letrozole treatment 
significantly decreased ovarian tumor burden when compared to sham treated controls. We have 
developed an animal model, which will serve as a powerful tool for exploring the involvement of 
steroid hormone signaling pathways in the etiology of ovarian tumors. 
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4.2- Introduction 
Ovarian cancer remains the most deadly gynecological cancer among women, largely 
because the majority of women are diagnosed after the cancer has become metastatic (47). A 
lack in early diagnosis indicates a deficiency of adequate tools to detect this disease in its 
infancy. The development of animal models with ovarian cancer will give medical investigators 
insight into the establishment and progression of this disease in vivo. This information is critical 
for developing diagnostic tools to detect ovarian cancer in its early stages, an essential step in 
lowering the death rate due to ovarian cancer.  
Several types of ovarian tumors exist depending on the cellular origin of the tumor. 
Epithelial ovarian tumors account for approximately 90% of all ovarian cancers in the western 
world (59). The majority of these cancers fall into 1 of 4 main histotypes: serous, endometrioid, 
mucinous, or clear cell. In the western world serous ovarian tumors account for 70% of all 
ovarian cancers (60).  
Because of progressive research in the past decade, biochemical markers have been 
identified to determine the histotype of epithelial ovarian cancer. The up-regulation of Wilms 
tumor 1 (WT1) along with ovarian tumor expression of paired homeobox 8 (PAX8) are used to 
diagnose serous ovarian tumors from other epithelial ovarian tumor types (71).   
The incidence of ovarian serous carcinoma increases as a woman ages, with an average 
patient age of 56 years (72). Several epidemiologic studies suggest that there is an increased risk 
of ovarian cancer for post-menopausal women taking hormone replacement therapy, either 
estrogen or estrogen in combination with progesterone (67-70). This leaves the possibility that 
high steroid hormone levels, in combination with the high gonadotropin levels characteristic of 
post-menopausal women, may drive ovarian tumorigenesis.  
The etiology of ovarian tumorigenesis remains largely unknown. Undoubtedly, this is a 
result in a lack of adequate animal models to use for in vivo investigation of this disease. To date, 
there have been a few mouse models created that develop epithelial ovarian tumors. The existing 
mouse models for ovarian epithelial tumors involve inactivation of various tumor suppressors 
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such as PTEN, APC, p53, and RB, or over-expression of known tumor promoters such as c-myc, 
Kras, and Akt, through intrabursal administration of adenoviral vectors (61-66). Although these 
tumor models have provided valuable information regarding the gene dysfunction required for 
tumorigenesis, the aggressiveness and rapidity of tumor formation in these models limit 
identification of early biomarkers. Furthermore, gene deletion or over-expression via bursal 
injections of adenoviruses does not allow establishment of a permanent line for therapeutic 
studies. Thus, despite generating ovarian tumors, these mouse models have limited usefulness 
because of their dependence on strong oncogenic signals that may not reflect the true progression 
of genetic changes that lead to ovarian cancer in humans.  
In this study, we introduce a transgenic mouse model, ERαd/d mice, in which ovarian 
tumors develop with 100% penetrance. The onset and progression of tumorigenesis in these mice 
is considerably slower compared to other models that have been reported previously. In this 
model, conditional deletion of ERα in the anterior pituitary, without affecting its expression in 
the ovary, leads to a systemic hormonal imbalance that drives ovarian tumorigenesis. The ERαd/d 
ovarian tumors over-express WT1 and PAX8, two known biochemical markers of human serous 
epithelial ovarian tumors. This novel animal model will be useful to examine epithelial ovarian 
tumorigenesis in vivo.  
 
4.3- Results 
Mature Adult ERαd/d Mice Develop Ovarian Tumors with 100% Penetrance 
We have created a transgenic mouse model that forms ovarian tumors by five months of 
age with 100% penetrance (Fig. 4.1A). These conditional knockouts of the ERα gene were 
created by employing the Cre-LoxP strategy. Transgenic mice expressing Cre under the control 
of progesterone receptor (PR) promoter, termed PR-cre mice, were crossed with mice harboring 
the ‘floxed’ ERα gene (ERαf/f) to create the ERαd/d mice in which the ERα gene is deleted in 
cells expressing PR (38-39). The PR-cre transgenic mouse has been previously used to 
effectively knockdown gene expression in the uterus (25). Interestingly ERαd/d mice form large 
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ovarian tumor masses but the global ERα knockout mice and ERαf/f control mice do not develop 
ovarian tumors (Fig. 4.1B). Tumor masses progressively enlarge in the ERαd/d mice with age and 
grow as large as 11 mm in size and weigh an average of 300 mg by eight months of age. Due to 
the burden of this large tumor mass on the stomach and intestines, ERαd/d mice die between 8-11 
months of age because they fail to eat.  
The histology of these ovarian tumors has been analyzed (Fig. 4.1C). The stromal 
compartment of ERαd/d ovarian tumors appears disorganized as early as 3 months of age. At 6 
months of age ERαd/d ovarian surface epithelium begins to invaginate within the ovarian tumor. 
By 11 months of age, when full-blown tumors arise, many cells with epithelial morphology can 
be seen within the ERαd/d ovarian tumor.   
 
Ovarian Tumor Cells in ERαd/d Mice are Hyperproliferative and Express Elevated Levels of  
Phosphorylated AKT at Ser 473  
To assess the proliferation status of cells within the ovarian tumors of ERαd/d mice, we 
performed immunohistochemical analysis using an anti- proliferating cell nuclear antigen 
(PCNA) antibody, a well known proliferation marker. As expected ERαf/f mouse ovaries 
revealed a high level of proliferation in the granulosa cells, but ovarian surface epithelial (OSE) 
cells remained quiescent. ERαd/d mice at 6 months of age also possessed follicles with 
proliferating granulosa cells. However, in sharp contrast to ERαf/f mouse ovaries, ERαd/d ovarian 
tumors contained hyperproliferative surface epithelial cells as well as tumor cells within the 
ovary (Fig. 4.2A). 
The phosphorylated AKT (p-AKT), the active form of the protein, is a critical player in 
cancer cell proliferation in multiple cancerous tissues. Ovarian cancer cells express high levels of 
p-AKT to promote tumor cell proliferation (73-74). To investigate the role that p-AKT might 
play in ERαd/d ovarian tumor cell proliferation, we employed immunohistochemical analysis 
using an antibody against p-AKT. ERαf/f ovaries express very low levels of p-AKT in the OSE. 
ERαd/d ovarian tumors, however, express prominent expression of p-AKT in the OSE as well as 
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in tumor cells, the same cell types that are hyperproliferative as marked by PCNA (Fig. 4.2B).  
High expression of p-AKT in proliferating tumor cells suggests that p-AKT plays a role in 
ERαd/d ovarian tumor cell proliferation.  
 
ERαd/d Mouse Tumors are Epithelial Cell Ovarian Tumors  
Ovarian tumors can arise from multiple cell types within the ovary. Two of the most 
common ovarian tumors are granulosa cell tumors and epithelial cell tumors. To determine the 
type of ovarian tumor in the ERαd/d mice, we first employed immunohistochemical analysis 
using an antibody against anti-mullerian hormone (AMH), a well known marker for granulosa 
cells and granulosa cell tumors (75). Both ERαf/f and ERαd/d ovaries expressed AMH exclusively 
in granulosa cells within follicles (Fig. 4.3A). ERαd/d ovaries did not express AMH in the tumor 
cells indicating that the ovarian tumors are not of granulosa cell origin.  
We next performed immunohistochemical analysis using anti-cytokeratin 8 antibody to 
determine if these tumors are of an epithelial cell type. ERαf/f mice of 3, 6, and 11 months of age 
express cytokeratin 8 exclusively in the OSE (Fig. 4.3B). ERαd/d mouse ovaries at 3 months of 
age express cytokeratin 8 exclusively in the OSE.  However, OSE cells of ERαd/d mice at 3 
months of age aggregate in multiple layers, an abnormality for the OSE. At 6 months of age, 
ERαd/d mouse ovaries begin to show cytokeratin 8 within the ovary indicating that the ovarian 
tumor contains epithelial cells. By 11 months of age nearly the entire ERαd/d mouse ovarian 
tumor expresses cytokeratin 8, indicating that this ovarian tumor is of epithelial cell origin.  
 
ERαd/d Mouse Epithelial Ovarian Tumors Mimic Human Serous Epithelial Ovarian Tumors 
It is well known that the majority of ovarian epithelial tumors are one of four different 
histotypes: serous, endometroid, mucinous and clear cell. The American Cancer Society reports 
that over 80% of all human epithelial ovarian tumors are characterized as serous and display 
characteristics of Fallopian tube epithelium.  Recent studies have revealed biochemical markers 
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that will identify each histotype of ovarian epithelial cancer. Nonaka, et al. report that the 
expressions of WT1 together with PAX8, a protein normally expressed by the Fallopian tube 
epithelium, are characteristic specifically of the serous epithelial ovarian tumor (71). We 
employed these biochemical markers to further characterize the epithelial ovarian tumors of 
ERαd/d mice.  
WT1 is not expressed in the nucleus of any ovarian cell type of ERαf/f mice. Abundant 
nuclear WT1 is expressed in both OSE and ovarian tumor cells of ERαd/d mice (Fig. 4.4A). In 
addition, PAX8 is highly expressed in ovarian tumor cells but is absent in the OSE of ERαd/d 
mice, an expression pattern that is similar to human serous ovarian cancer (Fig. 4.4B). In 
contrast, ERαf/f mouse ovaries do not express PAX8, but the Fallopian tube epithelium exhibits 
high expression of nuclear PAX8. These data indicate that ERαd/d ovarian tumors mimic human 
serous type of epithelial ovarian tumors. 
 
ERαd/d Mouse Epithelial Ovarian Tumors Express Similar Genes as Human Serous Epithelial 
Ovarian Tumors 
We assessed possible similarities between ERαd/d ovarian tumors and human serous 
tumors by analyzing mRNA expression of several genes known to be up-regulated in human 
serous tumors.  Platelet derived growth factor receptor (PDGFR) is over-expressed in human 
serous ovarian tumors and is targeted in clinical trials as a treatment for ovarian cancers (85-86). 
ERαd/d ovarian tumors, like human serous ovarian tumors, express high levels of PDGFR at 3, 6, 
and 11 months of age (Fig. 4.5A).  Vascular cell adhesion molecule (VCAM) is found in the 
blood of cancer patients and has recently been proposed as a marker to detect early stages of 
ovarian cancer (87-88).  Elevated VCAM mRNA levels are overexpressed in ERαd/d ovarian 
tumors (Fig. 4.5B).  
Human ovarian tumors that are sensitive to cisplatin have an increased expression of 
trophinin, a membrane protein that is associated with cell adhesion. Human ovarian tumors 
resistant to paclitaxel express elevated levels of clusterin, a protein of unknown function (89-90). 
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Interestingly ERαd/d ovarian tumors express elevated levels of both trophinin and clusterin (Fig. 
4.5C&D). The precise molecular mechanism by which cisplatin and paclitaxel affect ovarian 
tumor growth is largely unknown. Employing ERαd/d mice to study ovarian tumorigenesis may 
aid in the discovery of underlying molecular mechanisms of these chemotherapies.  
We next analyzed the gene expression profile in ERαd/d ovarian tumors and compared the 
molecular fingerprint of ERαd/d ovarian tumors to that of human serous epithelial ovarian cancer. 
RNA was isolated from ERαd/d ovarian tumors and subjected to microarray analysis. A list of 
2620 genes were aberrantly expressed +/- 1.2 fold compared to ERαf/f ovaries. In order to 
compare this list to the molecular fingerprint of human serous epithelial ovarian cancer, three 
microarray studies comparing human serous ovarian adenocarcinoma to normal ovaries were 
exported from the Oncomine public database. These gene lists were compared to the list of 
aberrantly expressed genes in ERαd/d ovarian tumors using Ingenuity Pathway Analysis. This 
analysis indicated 25-40% similarity of aberrantly expressed genes in the ERαd/d ovarian tumors 
with that of human serous ovarian adenocarcinoma (Table 4.1). This is a remarkable similarity 
considering these mRNA fingerprints of ovarian cancer are in two different species. Clearly 
ERαd/d is a promising mouse model to study the human serous ovarian tumorigenesis.  
 
Differential Loss of ERα in the HPO Axis of ERαd/d Mice Results in a Loss of Estrogen 
Negative Feedback on the HPO Axis 
The finding that ERαd/d mice develop ovarian tumors while global ERα knockout do not 
develop these tumors remained a puzzling phenomenon until we investigated the expression of 
ERα in the HPO axis of ERαd/d mice. It is known that PR is expressed in all organs among the 
hypothalamus-pituitary-ovarian (HPO) axis (76). Along with PR ERα is also known to be 
expressed in these same organs (77). We determined if PR-cre was able to create a functional 
loss of ERα in the hypothalamus, pituitary and ovary of ERαf/f and ERαd/d mice. 
In the hypothalamus of ERαf/f mice, ERα is expressed in the hypothalamus near the third 
ventricle, and this expression remains intact in the hypothalamus of ERαd/d mice (Fig. 4.6A&B). 
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Pituitary expression of ERα is wide-spread in the anterior lobe of the ERαf/f mice (Fig. 4.6C). 
Expression of ERα is nearly ablated in the ERαd/d mice leaving the possibility that these mice 
may experience a loss of estrogen negative feedback on the HPO axis (Fig. 4.6C). Interestingly, 
ERα within the ERαd/d mouse ovary remains intact (Fig. 4.6G&H). Specifically, the OSE and 
ovarian tumor cells maintain ERα expression. Clearly the pituitary is the only organ within the 
HPO axis to experience a loss of ERα in the ERαd/d mice.  
 
ERαd/d Mice Have Elevated Levels of Circulating Hormones 
We next evaluated serum steroid hormones and gonadotrophin levels in ERαf/f, ERαd/d, 
and ERα KO mice. Unexpectedly serum estradiol levels were notably increased in the ERαd/d 
mice compared to both ERαf/f and ERα KO mice (Table 4.2).  Similarly, progesterone levels and 
testosterone levels also were markedly higher in the ERαd/d mice compared to both ERαf/f and 
ERα KO mice. LH levels in the ERαd/d mice remained higher than the ERαf/f mice but were 
comparable to ERα KO mice. Interestingly, serum follicle stimulating hormone (FSH) was not 
statistically different between ERαd/d, ERαf/f, or ERα KO mice. It is likely that the high hormone 
signature of the ERαd/d mice plays a role in driving ovarian tumorigenesis.  
 
ERαd/d Mice Display Aberrant ERα Signaling within Ovarian Tumors  
Because ERαd/d mouse ovaries maintain functional ERα and extreme high levels of 
serum estrogen, we evaluated ERα signaling in the ERαd/d mouse ovarian tumors. 
Phosphorylated ERα(p- ERα) is the active form of ERα and positively influences the 
transcriptional ability of both liganded and unliganded ERα (78-79). Phosphorylation of 
ERα, specifically at Ser-118, occurs in human breast tumors, is activated by the MAPK pathway 
and plays a functional role in human breast tumor tamoxifen resistance (80-81). We analyzed p-
ERα expression at Ser-118 in ERαf/f ovaries and ERαd/d ovarian tumors. Although p-ERα is 
  
 
 
 
59 
 
expressed at low levels in ERαf/f ovaries, ERαd/d ovarian tumors show extensive p-ERα 
expression in the OSE (Fig. 4.7C). 
 
Aromatase is Highly Expressed in Interstitial Cells of ERαd/d OvarianTumors  
 ERαd/d mice have very high levels of circulating estradiol (Table 4.2). We investigated 
the cellular origin of estradiol in this mouse model. ERαd/d ovarian tumors express a 5-fold 
increase in aromatase mRNA when compared to ERαf/f ovaries (Fig. 4.8A). We next localized 
aromatase expression in interstitial cells within the ERαd/d ovarian tumors. Cells were released 
from ovarian tumors and then cultured in vitro. Immunocytochemistry was employed to co-
localize aromatase with either cytokeratin, an epithelial cell marker, or vitmentin, an interstitial 
cell marker. Epithelial cells derived from the tumors stained positive for cytokeratin (Fig. 4.8B) 
but did not stain positive for aromatase (Fig. 4.8C). However, cells expressing vimentin (Fig. 
4.8E) also stained positive for aromatase (Fig. 4.8F). These data confirm that aromatase is over-
expressed in interstitial cells of ERαd/d ovarian tumors.  
 
Letrozole Treatment Decreases Ovarian Tumor Volume  
 To address the role of aromatase in ERαd/d ovarian tumorgenesis, we treated mice with 
letrozole, an aromatase inhibitor, for three consecutive months. ERαd/d mice treated with 
letrozole developed tumors that were 60% smaller than ERαd/d mice treated with a sham control 
(Fig. 4.9 A&B). However, ovarian tumors in letrozole treated ERαd/d mice were still larger than 
the ERαf/f control ovaries. Letrozole effectively decreased estradiol serum levels without 
effecting LH serum levels in these mice (Fig. 4.9C). These data support the conclusion that 
letrozole effectively decreases ovarian tumor volume by specifically decreasing estradiol levels.  
We analyzed the impact of letrozole on several biochemical markers of ovarian tumors. 
Letrozole significantly decreased expression of PDGFRα, VCAM, clusterin and trophinin (Fig. 
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4.10A-D).  These molecules are known to be up regulated in human ovarian cancer and ERαd/d 
ovarian tumors. We also analyzed the expression of Wip1, a known target of estrogen in MCF7 
cells. Letrozole also decreased the mRNA and protein expression of this estrogen regulated gene 
further confirming that letrozole effectively decreases tumor volume by regulating estrogen 
signaling in ERαd/d mice. 
 
4.4- Discussion 
It is predicted that 21,880 cases of ovarian cancer will be diagnosed in 2010 and 13,850 
deaths will occur as a result of ovarian cancer (47). This high mortality rate is a direct result of 
late stage diagnosis for 60% of ovarian cancer cases. In sharp contrast, women diagnosed with 
stage I ovarian carcinoma have a 90% 5 year survival rate (91). Undoubtedly the mortality rate 
associated with ovarian cancer will improve with more early diagnoses of ovarian cancer. To 
improve the survival rate for women with ovarian cancer, we need tools that allow researchers to 
investigate the early stages of tumorigensis. In the present study we introduce a transgenic mouse 
model, ERαd/d mouse, that develops ovarian tumors at a slow rate due to a physiological 
perturbation and not a mechanical disturbance such as intrabursal injection of adenovirus. This 
mouse model presents an invaluable tool to study molecular markers and targets of early ovarian 
tumorigenesis.  
Almost all ovarian carcinomas develop from epithelial ovarian tumors with serous tumors 
representing the most frequent histotype of epithelial tumors in humans. ERαd/d mouse ovarian 
tumors over-express WT1 much like human cases of serous tumors in which WT1 is used as a 
biochemical marker to diagnose serous epithelial ovarian tumors (92). However, WT1 is also up-
regulated in other types of ovarian tumors such as sertoli cell ovarian tumors (93). To validate 
ERαd/d mouse ovarian tumors as a model for serous ovarian tumors we analyzed the expression 
of PAX8 within these ovarian tumors. PAX8 is present developmentally in the Mullerian duct 
and continues to be expressed in the epithelium of the fallopian tube after duct differentiation 
(94). Normally PAX8 is not expressed in the ovary but PAX8 is over-expressed in serous 
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epithelial ovarian carcinomas (95).  ERαd/d mouse ovarian tumors also over-express PAX8. 
These data lead us to believe that ERαd/d mice will be a useful model to study serous ovarian 
tumorigenesis.  
Although the fallopian tube epithelium is quiescent in ERαd/d mice, the hyper-
proliferation status of the OSE is remarkable considering the OSE does not proliferate most of 
the time. Consistent with this observation we noted an over-expression of p-ERα (Ser 118) in the 
OSE of ERαd/d mice. This finding leads us to believe that ERα signaling is at the heart of 
epithelial ovarian tumorigenesis. Several epidemiologic studies indicate that women taking 
hormone replacement therapy during or after menopause, a time when women have high levels 
of gonadotropin levels, have an increased risk of ovarian cancer. Similar to postmenopausal 
women using hormone replacement therapy, ERαd/d mice experience high levels of steroid 
hormones along with high levels of gonadotropins. The unique eleveated hormone milieu of 
ERαd/d mice provides a unique model to better understand the role of these hormones in 
epithelial ovarian tumorigenesis.  
Gene expression analysis indicates that many genes which are over expressed in human 
ovarian cancers are also up-regulated in ERαd/d ovarian tumors. These over expressed genes 
include PDGFRα, VCAM, clusterin and trophin. We next compared molecular finger prints of 
human serous ovarian cancer and ERαd/d ovarian tumors by using microarray analysis. Even 
though this comparison is between cancers from two different species there is still 40% 
homology in aberrantly regulated genes. These results support the conclusion that ERαd/d ovarian 
tumors mimic human serous ovarian cancer and these mice are an excellent tool for studying this 
pathophysiology.  
ERαd/d mice have high circulating estradiol levels. We confirm that ERαd/d ovarian 
tumors over express aromatase and localize this aromatase expression to insterstitial cells within 
the ovarian tumor. The production of aromatase from the interstitial cells acts on epithelial cells 
to drive tumorigenesis. Estradiol is known to drive cancer development in other systems such as 
breast cancer. Using the ERαd/d animal model we show that letrozole treatment decreases ovarian 
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tumor volume by 60%. However tumor volume still remained larger than ERαf/f ovaries. In this 
study three month old mice were treated for three months. Even though three month old ERαd/d 
mice do not exhibit full-blown ovarian tumors, it is possible that the initial phases of 
tumorigenesis have already begun. Future studies will address the ability of letrozole to 
completely inhibit ovarian tumor formation. Our initial experiments clearly indicate that 
letrozole effectively decreases tumor volume. Clearly more clinical studies are needed to 
determine if there is a population of women with ovarian cancer that can benefit from this 
treatment.  
In summary, we have generated a novel transgenic mouse model, ERαd/d mouse, which 
develops a slow progression of epithelium ovarian tumorigenesis. Due to a lack of estrogen 
negative feedback on the HPO axis at the level of the pituitary, these mice secrete high levels of 
steroid hormones and LH, a hormone milieu that mimics a post-menopausal women taking 
hormone replacement therapy. Using established biochemical markers, we have determined that 
these ovarian tumors over-express similar molecules to that of women with serous ovarian 
cancer. Furthermore treatment of these mice with letrozole significantly decreases ovarian tumor 
volume establishing ERαd/d mice as a hormone dependant murine model of ovarian 
tumorigenesis. Undoubtedly this unique animal model will be a powerful tool for studying the 
early events of ovarian tumorigenesis.  
 
4.5- Materials and Methods 
Hormone Assay 
All hormone assays were completed by the University of Virginia Center for Research in 
Reproduction Ligand Assay and Analysis Core. Statistical significance was determined on SAS 
program using the Tukey procedure to control for comparison-wise error rate. Significance 
cutoff value of p<0.05 was determined to be statistically significant.   
 
 
  
 
 
 
63 
 
Immunohistochemistry 
Immunohistochemistry was carried out as previously described. Specfic antibodies wer obtained 
from the following: cytokeratin 8 (Developmental Studies Hybridoma Bank -TROMA I), 
cytokeratin 19 (Developmental Studies Hybridoma Bank -TROMA III), PCNA (Santa Cruz  sc-
56), AMH (Compliments of Wylie Vale), WT1 (Santa Cruz sc-846), PAX8 (Proteintech group 
10336-1-AP), calretinin (Invitrogen 180291), Ber-EP4 (DAKO), aromatase (Abcam ab35604) 
vimentin (Sigma Aldrich V5255), PPM1D/Wip1 (Sigma Aldrich HPA022277). 
 
Immunocytochemistry 
Ovarian tumor cells were cultured in 2 or 4 well chamber slides. Cells were fixed with 10% 
formalin solution for 10 minutes. Cells were washed with HBSS then treated with 25% triton X-
100 (Sigma Aldrich) in PBS for an additional 10 minutes. Cells were washed with HBSS and 
exposed to a blocking serum for 1 hour. Cells were then treated with primary antibodies and 
incubated at 40C overnight. Cells were then washed with PBS and exposed to cy3 or cy5 
conjugated secondary antibodies for 1 hour at room temperature.   
 
Isolation of Ovarian Cells 
Ovarian tumors were removed from mice after euthanasia with carbon dioxide. Ovarian tumors 
were either digested with 6 g/liter dispase (Invitrogen) and 25g/liter pancreatin, or 0.5 g/liter 
collagenase in Hanks balanced salt solution (HBSS). After incubation for 1 hour at 37 °C, the 
tubes were vortexed for 10-12 s until the supernatant became turbid with dispersed cells. The 
contents of the tube were then passed through a 80-µm gauze filter (Millipore). Cells were 
resuspended in Dulbeccos modified Eagle's Medium-F12 medium (DMEM-F12; with 100 
unit/liter penicillin, 0.1 g/liter streptomycin, 1.25 mg/liter fungizone) containing 10% heat-
inactivated fetal calf serum and live cells were assessed by trypan blue staining using a 
hemocytometer. Cells were seeded in 2 or 4 well chamber slides.  The unattached cells were 
removed by washing with HBSS, and cell culture was continued for 48 hrs after addition of fresh 
medium. 
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Silastic capsule implant 
Silastic capsules were made by sealing silastic laboratory tubing (1.57 mm I.D. x 2.41 mm O.D.) 
with medical adhesive silicone type A (Dow Corning).  Femara 2.5 mg tablets (Novartis) 
containing letrozole were ground with a mortar and pestle. Capsules were filled with .8 mg of 
Femara tablets and sealed with medical adhesive silicone type A.  
 
Mice treated with analgesic (buprenorphine 0.05 mg/kg s.c.) 1 hour prior to surgery. Mice were 
anesthetized with ketamine/xylazine 87 mg/kg; 15 mg/kg. A small incision through the skin was 
made dorsally just below the neck and the silastic capsule was inserted underneath the skin. The 
incision was held together with wound clips until healed. After 3 months of exposure to either 
empty silastic capsules (sham control) or silastic capsules containing letrozole mice were 
euthanized with carbon dioxide and ovarian tumors were fixed or frozen.   
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4.6- Figures and Tables 
 
 
            
 
 
 
 
 
 
Fig. 4.1: ERαd/d Mice Display 
Ovarian Tumors by 5 Months of 
Age. (A) Bilateral ovarian tumors of 
ERαd/d mouse at 11 months of age. 
(B) Gross morphology of ERαd/d, 
ERαf/f, and ERα global knockout 
mouse (KO) ovaries at 3, 5, and 8 
months of age. (C) Histological 
sections of ERαf/f ovaries at 3 months 
of age and ERαd/d ovarian tumors at 
3, 6, and 11 months of age. Sections 
were stained with hemotoxylin and 
eosin and pictures were taken at 4x 
and 10x. 
Fig. 4-1 B 
Fig. 4-1 A 
Fig. 4-1 C 
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Fig. 4.2: ERαd/d Ovarian Tumors are Hyperproliferative. (A) Immunohistochemistry 
of ERαf/f ovaries and ERαd/d ovarian tumors at 6 months of age using anti-PCNA 
antibody. Arrows point to hyperproliferative OSE and tumor cells in ERαd/d ovarian 
tumors. (B) Immunohistochemistry of ERαf/f ovaries and ERαd/d ovarian tumors at 11 
months of age using anti-p-AKT antibody (Ser 473). 
Fig. 4-2 A 
Fig. 4-2 B 
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Fig. 4.3: ERαd/d 
Ovarian Tumors are 
Epithelial Cell 
Tumors Not 
Granulosa Cell 
Tumors.  
(A) 
Immunohistochemistry 
of ERαf/f ovaries and 
ERαd/d ovarian tumors 
at 11 months of age 
using an antibody 
against AMH.  
(B) 
Immunohistochemistry 
of ERαf/f ovaries at 3 
months of age and 
ERαd/d ovarian tumors 
at 3, 6, and 11 months 
of age using anti-
cytokeratin 8 antibody.  
Fig. 4-3 A 
Fig. 4-3 B 
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Fig. 4-4: ERαd/d 
Ovarian Tumors 
Express Elevated 
Biochemical 
Markers, WT1 and 
PAX8, of Human 
Serous Epithelial 
Ovarian Tumors.  
(A) 
Immunohistochemistr
y of ERαf/f ovaries and 
ERαd/d ovarian tumors 
at 11 months of age 
using an antibody 
against WT1. Pictures 
are taken at 20x and 
40x.  
Fig. 4-4 A 
Fig. 4-4 B 
ERαf/f 
ERαd/d 
ERαd/d 
ERαf/f 
ERαd/d 
(B) 
Immunohistoch
emistry of 
ERαf/f ovaries 
and ERαd/d 
ovarian tumors 
at 11 months of 
age using an 
antibody against 
PAX8. Pictures 
for ERαf/f 
ovaries are 
taken at 10x and 
20x. Pictures 
for ERαd/d 
ovarian tumors 
are taken at 20x 
and 40x. 
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Fig. 4.5: ERαd/d Ovarian Tumors 
Express High Levels of Genes 
Known to be Up-regulated in 
Human Ovarian Tumors. ERαf/f 
ovaries and ERαd/d ovarian tumors at 
3, 6, and 11 months of age are 
isolated. Gene expression of 
PDGFRα (Α), VCAM (B), trophinin 
(C), and clusterin (D) is measured by 
qPCR analysis of mRNA isolated 
from ovaries or ovarian tumors. * 
indicates a significant difference in 
gene expression between mice with 
different genetic backgrounds at a p-
value cutoff of 0.05 using a student’s 
t-test.  
 
A 
B 
C 
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Table 4.1: Microarray Analysis indicates a High Level of Similarity Between 
Aberrantly Expressed Genes in ERαd/d Ovarian Tumors and Human Ovarian 
Serous Adenocarcinoma. ERαf/f ovaries and ERαd/d ovarian tumors are collected, 
mRNA extracted and subjected to microarray analysis. A list of 2620 aberrantly 
expressed genes +/- 1.2fold is generated.  This list is compared to gene lists from 3 
studies stored in the Oncomine database which compare gene expression in normal 
human ovaries vs. human ovarian serous adenocarcinoma. 25-40% of genes aberrantly 
expressed in ERαd/d ovarian tumors are common in human ovarian serous 
adenocarcimoma.   
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Fig. 4.6: ERαd/d Mice have Pituitary ERα Loss of Function but 
Maintain ERα Function in the Hypothalamus and Ovary. Histological 
sections of ERαf/f (A) and ERαd/d (B) hypothalami immunostained for 
ERα protein. Histological sections of ERαf/f (C) and ERαd/d (D) pituitaries 
immunostained for ERα protein. Histological sections of ERαf/f ovaries 
(E&F) and ERαd/d ovarian tumors (G&H) immunostained for ERα protein.  
ERαf/f ERαd/d 
A B 
C D 
E F 
G H 
  
 
 
 
72 
 
 
Hormone  ERa
f/f
  ERa
d/d
  ERa KO  
Estradiol (pg/ml)  7.03 +/- 0.84 
A
  63.51 +/- 36.30 
B
  19.28 +/- 2.61 
C
  
Progesterone (ng/ml)  1.94 +/- 0.61 
A
  8.78 +/- 0.77 
B
  1.58 +/- 0.44 
A
  
LH (ng/ml)  .17 +/- 0.12 
A
  2.31 +/- 0.51 
B
  2.90 +/- 0.43 
B
  
FSH (ng/ml)  6.30 +/- 1.58 
A
  2.92 +/- 0.57 
A
  4.66 +/- 0.27 
A
  
Testosterone (ng/ml)  3.01 +/- 1.35 
A
  394.85 +/- 59.058 
B
  32.01 +/- 11.39 
C
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2: Serum steroid hormone and gonadotrophin concentrations in ERαd/d, ERαf/f, 
and ERα KO mice.  Hormone levels are displayed as the average +/- s.e.m.  Tukey analysis 
was utilized for statistical signficance. Different letters indicate statistical difference at p 
value cutoff of 0.05. 
Fig. 4.7: ERαd/d ovarian tumors express high levels of p- ERα Immunohistochemistry of 
ERαf/f ovaries and ERαd/d ovarian tumors at 11 months of age using an antibody against p-
ERα (Ser 118).  
ERαf/f 
ERαd/d 
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Fig. 4.8: ERαd/d Ovarian Tumors Interstitial Cells Express High Levels of Aromatase. (A) 
QPCR indicating higher mRNA levels of aromatase in ERαd/d compared to ERαf/f ovaries. 
ERαd/d ovarian tumors are digested and single cell suspensions are cultured for 48 hours. 
Epithelial cells are stained with anti-cytokeratin 8 (A) and anti-aromatase (B) antibodies. 
Overlap of A and B is represented in picture C. Dapi counterstain is blue. Interstitial cells are 
stained with anti-vimentin (E) and anti-aromatase (F) antibodies. Overlap of E and F is 
represented in picture G. Yellow indicates co-localization of vimentin and aromatase. * 
indicates a significant difference in gene expression between mice with different genetic 
backgrounds at a p-value cutoff of 0.05 using a student’s t-test.  
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Fig. 4.9: Letrozole Treatment, an Aromatase Inhibitor, Decreases ERαd/d Ovarian 
Tumor Volume. Three month old ERαd/d and ERαf/f mice were treated with either 
letrozole filled silastic capsules or empty capsules (sham) for a period of three months. 
Gross morphology comparing ERαd/d ovarian tumors after treatment with letrozole 
(left) ERαd/d ovarian tumors untreated (right). Ovarian tumor volume of ERαd/d mice 
treated with letrozole is 60% smaller on average than ovarian tumor volume of ERαd/d 
mice untreated, p=0.02(B). Letrozole treatment is effective in reducing serum estradiol 
levels but does not decrease LH levels (C). 
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Fig. 4.10: Letrazole Treatment 
Decreases Expression of ERαd/d 
Ovarian Tumors Genes that are 
Known to be Up-regulated in 
Human Ovarian Tumors. ERαd/d 
mice are treated with letrozole or 
sham silastic capsules for three 
months. Gene expression of 
PDGFRα (Α), VCAM (B), trophinin 
(C), clusterin (D) and Wip1 (E) is 
measured by qPCR analysis of 
mRNA isolated from ovarian tumors 
of untreated ERαd/d mice or ERαd/d 
mice treated with letrozole.  
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Fig. 4.11: ERαd/d Ovarian Tumors Treated with Letrozole Express Lower Levels 
of Wip1 protein, an Estrogen Regulated Gene. ERαd/d mice are treated with 
letrozole or sham silastic capsules for three months. ERαd/d untreated ovarian tumors 
express high levels of Wip1 nuclear protein (A&B). ERαd/d letrozole treated ovarian 
tumors have decreased Wip1 protein expression comparatively (C&D).  
A B 
C D 
ERαd/d 
Sham 
Treatment 
ERαd/d 
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